Gene therapy

AAV vectors delivering Factor I or Factor H to the eye modulate the complement system, effectively reducing geographic atrophy and improving vision in AMD by enhancing C3b and iC3b degradation, addressing the limitations of current treatments.

JP2024156706APending Publication Date: 2024-11-06SYNCONA IP HOLDCO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024112812
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-10-28
Filing Date
2024-07-12
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Current treatments for age-related macular degeneration (AMD), particularly dry AMD, are inadequate for all patients, with many not responding to anti-VEGF antibodies and requiring frequent intravitreal injections, and there is a need for novel approaches to modulate the complement system to address complement-mediated disorders.

Method used

The use of adeno-associated virus (AAV) vectors to deliver Factor I or Factor H, or their fragments, to the eye to modulate the complement C3b feedback cycle, thereby regulating C3b and iC3b degradation, reducing inflammation and preventing geographic atrophy in AMD.

Benefits of technology

The AAV vectors increase C3b-inactivating and iC3b-degrading activities in the eye, potentially reducing geographic atrophy by 10-90% over 12 months and improving visual acuity, while avoiding systemic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156706000001_ABST
    Figure 2024156706000001_ABST
Patent Text Reader

Abstract

To provide a vector useful for treating or preventing a complement-mediated disorder of the eye.SOLUTION: An AAV vector comprising a nucleotide sequence encoding Factor I or a fragment or derivative thereof is provided.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a compound for use in gene therapy of ocular diseases. More specifically, the present invention relates to an adeno-associated virus (AAV) vector for use in the treatment or prevention of age-related macular degeneration (AMD), which vector allows the delivery of factor I and / or factor H or a fragment or derivative thereof to the eye. [Background technology]

[0002] The macula is a small area of ​​the retina of the eye, approximately 3-5 millimeters in size, adjacent to the optic nerve. The macula is the most sensitive area of ​​the retina, allowing for high visual acuity, and contains the fovea, a recessed area that contains a high density of cones (photoreceptors responsible for color vision).

[0003] Age-related macular degeneration (AMD) is the most common cause of functional blindness in people over the age of 50 in developed countries (Seddon, J M. Epidemiology of age-related macular degeneration. In:Ogden, TE, et al., eds. Ryan SJ, ed-in-chief. Retina Vol II. 3rd ed. St. Louis, Mo.:Mosby;2001:1039-50). AMD is associated with neovascularization that originates from the choroidal vasculature and extends into the subretinal space. In addition, AMD is characterized by progressive degeneration of the retina, retinal pigment epithelium (RPE), and the underlying choroid (a highly vascular tissue located between the retina and the sclera, below the RPE).

[0004] A variety of factors may contribute to the pathogenesis of AMD, including oxidative stress, inflammation with a possible autoimmune component, genetic background (eg, mutations), and environmental or behavioral factors such as smoking and diet.

[0005] The clinical progression of AMD is characterized by multiple stages depending on the changes in the macula. Early AMD is characterized by drusen, which are accumulations of extracellular blood debris beneath the retina that appear as yellowish spots within the retina on clinical examination and fundus photography. Drusens are classified according to their size as small (<63 μm), medium (63–124 μm), and large (>124 μm). Drusens are also considered hard or soft depending on the appearance of their margins on ophthalmic examination. Hard drusen have clearly defined margins, whereas soft drusen have unclear and fluid margins. The Age-Related Eye Disease Study (AREDS) Fundus Photography Severity Scale is one of the main classification systems used for the disease.

[0006] AMD is classified into "dry" and "wet" (exudative or neovascular) forms. Dry AMD is more common than wet AMD, but the dry form can progress to the wet form, and the two forms occur together in a significant number of cases. Dry AMD is typically characterized by progressive apoptosis of cells in the RPE layer, the overlying photoreceptor cells, and often the underlying choriocapillaris layer. Dense areas of RPE cell death accompanied by atrophy of the overlying photoreceptors are called geographic atrophy. Patients with this form of AMD experience a slow and progressive deterioration of central vision.

[0007] Wet AMD is characterized by bleeding and / or fluid leakage from abnormal blood vessels growing from the RPE and choroidal vessels (choriocapillaris) beneath the macula, which can contribute to sudden and disabling vision loss. It is presumed that such choroidal neovascularization (CNV) and its secondary complications are responsible for most of this vision loss experienced by patients. A subtype of neovascular AMD is called retinal angiomatous proliferation (RAP), where the angiomatous proliferation originates from the retina and extends posteriorly into the subretinal space, eventually connecting with choroidal neovascularization in some cases.

[0008] The complement system (CS) is involved in the pathogenesis of early AMD, as determined by the identification of CS components in drusen from the eyes of AMD patients. At least 129 drusen-deposited proteins have been identified in AMD, including various apolipoprotein species (E, B, or AI), several amyloid peptides (P, Aβ, or SA-I), TIMP-3, serum albumin, and certain proteins related to cellular functions (e.g., ATP synthase β subunit, scavenger receptor B2, and retinol dehydrogenase). Drusen from AMD also contain nearly all of the complement proteins, including regulatory proteins (CFH, complement receptor 1 (CR1), vitronectin, and clusterin), products of CS activation and degradation (C1q, C3, C3a, C3b, and C5a), and members of the terminal CS pathway, including isolated and complexed forms of MAC components (i.e., 5, 6, 8 (α, β, and γ), and 9). The accumulation of drusen may activate CS, triggering the local production of inflammatory mediators and attracting leukocytes, which then augment the local inflammatory state seen in AMD.

[0009] Current treatment options for AMD include photodynamic therapy with benzoporphyrins (Arch Ophthamol. 1999;117:1329-1345) and a number of therapies that target the vascular endothelial growth factor (VEGF) pathway. Examples of such VEGF-targeting therapies include the aptamer pegaptanib (N Engl J Med. 2004;351:2805-2816) and antibodies such as ranibizumab (N Engl J Med. 2006 Oct 5;355(14):1432-44) and bevacizumab (BMJ. 2010 Jun 9;340:c2459.). However, not all patients respond to treatment with anti-VEGF antibodies, and not all patients recover vision or progress to registered blindness.

[0010] Therapies for the treatment of geographic atrophy have been developed and are currently in phase III clinical trials (MAHALO trial by Genentech / Roche). Lampalizumab is a humanized monoclonal inhibitory antibody against complement factor D, administered by intravitreal injection to slow the progression of geographic atrophy. As shown in Figure 1, factor D is part of the C3b feedback ("amplification") cycle. Factor D is present at very low serum concentrations and is an essential component of the alternative pathway. Nevertheless, due to its small size (27 kDa), factor D is rapidly cleared by the kidney and rapidly resynthesized. The therapy requires monthly intravitreal injections.

[0011] There is a need in the art for new approaches to treating AMD. [Prior art documents] [Non-patent literature]

[0012] [Non-Patent Document 1] Seddon, J M. Epidemiology of age-related macular degeneration. In:Ogden, TE, et al., eds. Ryan SJ, ed-in-chief. Retina Vol II. 3rd ed. St. Louis, Mo.:Mosby;2001:1039-50 [Non-Patent Document 2] Arch Ophthamol. 1999;117:1329-1345 [Non-Patent Document 3] N Engl J Med. 2004;351:2805-2816 [Non-Patent Document 4] N Engl J Med. 2006 Oct 5;355(14):1432-44 [Non-Patent Document 5] BMJ. 2010 Jun 9;340:c2459 Summary of the Invention

[0013] The present inventors now provide an approach to modulate the complement system, which is useful, for example, for the treatment of AMD.The present inventors provide factor I, which is delivered by gene therapy, for the purpose of negatively regulating the complement C3b feedback cycle through targeting the degradation cycle (Figure 1).The resulting readjustment of the feedback loop of the alternative pathway promotes the degradation of C3b and iC3b, and thus removes the main disease factor of complement-mediated disorders, especially those with a fundamental defect in alternative pathway regulation.Alternatively, factor H can be used instead.

[0014] In one aspect, the present invention provides an adeno-associated viral (AAV) vector comprising a nucleotide sequence encoding factor I, or a fragment or derivative thereof. In another aspect, the present invention provides an adeno-associated viral (AAV) vector comprising a nucleotide sequence encoding factor H, or a fragment or derivative thereof. In another aspect, the present invention provides an adeno-associated viral (AAV) vector comprising a nucleotide sequence encoding an anti-factor D antibody. In another aspect, the present invention provides an adeno-associated viral (AAV) vector comprising a nucleotide sequence encoding an anti-complement component 5 (C5) antibody.

[0015] In one embodiment, the nucleotide sequence encoding factor I or a fragment or derivative thereof comprises: (a) a nucleotide sequence encoding an amino acid sequence having at least 70% identity to SEQ ID NO: 1 or 9; (b) a nucleotide sequence having at least 70% identity to SEQ ID NO: 2 or 8; and (c) the nucleotide sequence of SEQ ID NO: 2 or 8 The sequence comprises a sequence selected from the group consisting of:

[0016] Preferably, the nucleotide sequence encoding factor I or a fragment or derivative thereof encodes a protein having the native activity of factor I (e.g., a protein represented by SEQ ID NO: 1 or 9). For example, the nucleotide sequence encoding factor I or a fragment or derivative thereof may encode a protein having the ability to process C3b and iC3b into inactive degradation products. In other words, the factor I or a fragment or derivative thereof preferably retains C3b-inactivating activity and iC3b-degrading activity.

[0017] In a preferred embodiment, the nucleotide sequence encoding factor I or a fragment or derivative thereof encodes a protein having C3b-inactivating activity and iC3b-degrading activity.

[0018] In one embodiment, the nucleotide sequence encoding the factor H or a fragment or derivative thereof comprises: (a) a nucleotide sequence encoding an amino acid sequence having at least 70% identity to SEQ ID NO:3 (b) a nucleotide sequence having at least 70% identity to SEQ ID NO:4, and (c) the nucleotide sequence of SEQ ID NO:4 The sequence comprises a sequence selected from the group consisting of:

[0019] Preferably, the nucleotide sequence encoding factor H or a fragment or derivative thereof encodes a protein having the native activity of factor H, such as the protein set forth in SEQ ID NO: 3. For example, the nucleotide sequence encoding factor H or a fragment or derivative thereof may encode a protein having the ability to act as a cofactor for factor I-mediated cleavage of C3b and to increase the rate of dissociation of C3 and C5 convertases.

[0020] In another aspect, the invention provides a cell transfected with an AAV vector of the invention.

[0021] In another aspect, the invention provides a pharmaceutical composition comprising an AAV vector of the invention or a cell of the invention in combination with a pharma- ceutical acceptable carrier, diluent or excipient, hi a preferred embodiment, the pharmaceutical composition is for intraocular administration.

[0022] In one embodiment, the AAV vector comprises a chicken beta actin (CBA) promoter, e.g., operably linked to a nucleotide sequence encoding factor I or H, or a fragment or derivative thereof. In one embodiment, the AAV vector comprises a CAG promoter, e.g., operably linked to a nucleotide sequence encoding factor I or H, or a fragment or derivative thereof. In one embodiment, the AAV vector comprises a promoter having the nucleotide sequence of SEQ ID NO:5, e.g., operably linked to a nucleotide sequence encoding factor I or H, or a fragment or derivative thereof.

[0023] In one embodiment, the AAV vector comprises a cytomegalovirus (CMV) enhancer element, e.g., operably linked to a nucleotide sequence encoding factor I or H, or a fragment or derivative thereof.

[0024] In one embodiment, the AAV vector comprises a bovine growth hormone polyA signal, preferably having the nucleotide sequence of SEQ ID NO:6, operably linked to a nucleotide sequence encoding, for example, factor I or H, or a fragment or derivative thereof.

[0025] In one embodiment, the AAV vector comprises a woodchuck hepatitis post-transcriptional regulatory element (WPRE), preferably a WPRE having the nucleotide sequence of SEQ ID NO:7, operably linked to a nucleotide sequence encoding, for example, factor I or H, or a fragment or derivative thereof.

[0026] In a preferred embodiment, the AAV vector of the invention is in the form of a viral particle.

[0027] In a preferred embodiment, the AAV viral particle comprises an AAV2 genome and AAV2 capsid proteins. Preferably, the nucleotide sequence encoding factor I or H, or a fragment or derivative thereof, is operably linked to a CAG promoter, preferably a promoter having the nucleotide sequence of SEQ ID NO:5.

[0028] The AAV vectors, cells or pharmaceutical compositions of the invention may be used to treat or prevent eye disorders.

[0029] In one embodiment, the present invention provides an AAV vector, cell or pharmaceutical composition of the invention for use in the treatment or prevention of complement-mediated eye disorders.

[0030] In one embodiment, the disorder is associated with overactivity of the complement C3b feedback cycle and / or underactivity of the C3b degradation cycle (see FIG. 1). In one embodiment, the disorder is age-related macular degeneration (AMD) or diabetic retinopathy. In a preferred embodiment, the disorder is AMD, preferably dry AMD.

[0031] In one embodiment, the use is in a subject, i.e. (a) subjects with a lower than normal activity or concentration of factor I in the eye and / or serum, preferably a concentration of 0-30 or 0-20 or 0-10 μg / mL in serum, or an activity equivalent thereto, and / or (b) a subject who is heterozygous or homozygous for an age-related macular degeneration (AMD) associated SNP, preferably a rare factor I variant. The present invention is intended to treat or prevent disorders in the

[0032] In one embodiment, the use is in a subject, i.e. (a) a subject having a normal level of factor I activity or concentration in the eye and / or serum, preferably at least 30 μg / mL in serum, e.g., 30 to 40 μg / mL; and / or (b) subjects who do not carry a rare factor I variant allele The present invention is intended to treat or prevent disorders in the

[0033] In another aspect, the present invention provides the AAV vector, cell or pharmaceutical composition of the present invention for use in treating or preventing age-related macular degeneration (AMD).The AMD can be, for example, dry AMD.In a preferred embodiment, the AMD is dry AMD.

[0034] In another aspect, the present invention provides an AAV vector, a cell or a pharmaceutical composition of the invention for use in the treatment or prevention of diabetic retinopathy.

[0035] In one embodiment, the formation of geographic atrophy is prevented or reduced, hi another embodiment, the amount of geographic atrophy is reduced.

[0036] In certain embodiments, the progression of geographic atrophy is slowed, preferably by at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in the increase in area of ​​geographic atrophy over a 12 month period following administration to the treated eye of a subject, compared to the untreated eye over the same period.

[0037] In another aspect, the invention provides an AAV vector, cell or pharmaceutical composition of the invention for use in improving or restoring vision or visual acuity in a subject suffering from an ocular disorder, such as, for example, an ocular disorder disclosed herein. In another aspect, the invention provides an AAV vector, cell or pharmaceutical composition of the invention for use in alleviating reduced vision or visual acuity, such as reduced vision or visual acuity associated with an ocular disorder, such as, for example, an ocular disorder disclosed herein.

[0038] In another aspect, the invention provides an AAV vector, a cell or a pharmaceutical composition of the invention for use in improving or restoring reading speed in a subject, for example in a subject suffering from an ocular disorder, such as an ocular disorder disclosed herein. In another aspect, the invention provides an AAV vector, a cell or a pharmaceutical composition of the invention for use in reducing reduced reading speed in a subject, for example reduced reading speed associated with an ocular disorder, such as an ocular disorder disclosed herein.

[0039] In another aspect, the invention provides an AAV vector, cell or pharmaceutical composition of the invention for use in reducing or preventing loss of photoreceptors and / or retinal pigment epithelium (RPE), such as loss of photoreceptors and / or RPE associated with an ocular disorder, such as an ocular disorder disclosed herein.

[0040] In a preferred embodiment, the AAV vectors, cells or pharmaceutical compositions for use according to the invention are administered intraocularly, and the inventors recognize that local administration of such therapy provides a means to substantially achieve the required levels of complement factors for the purposes of treating or preventing complement-mediated eye disorders, such as AMD.

[0041] In one embodiment, the AAV vector, cell or pharmaceutical composition of the invention is administered to the eye of a subject by subretinal injection, direct retinal injection, suprachoroidal injection or intravitreal injection.

[0042] In a particularly preferred embodiment, the AAV vectors, cells or pharmaceutical compositions of the invention are administered to the subject's eye by subretinal injection.

[0043] In one embodiment, administration of an AAV vector, cell or pharmaceutical composition of the invention thereby increases the level of C3b-inactivating activity and iC3b-degrading activity in a subject, particularly in the eye of a subject, for example in the RPE of a subject. In another embodiment, administration of an AAV vector, cell or pharmaceutical composition of the invention thereby increases the level of C3b-inactivating activity and iC3b-degrading activity in a subject, particularly in the eye of a subject, for example in the RPE of a subject, to a level above normal levels in the eye.

[0044] In another aspect, the present invention provides a method for treating or preventing a complement-mediated eye disorder, comprising administering an AAV vector, cell or pharmaceutical composition of the present invention to a subject in need thereof.

[0045] In one embodiment, the disorder is associated with overactivity of the complement C3b feedback cycle and / or underactivity of the C3b degradation cycle. In one embodiment, the disorder is age-related macular degeneration (AMD) or diabetic retinopathy. In a preferred embodiment, the disorder is AMD, preferably dry AMD.

[0046] In another aspect, the present invention provides a method for treating or preventing age-related macular degeneration (AMD), comprising administering the AAV vector, cell or pharmaceutical composition of the present invention to a subject in need thereof.The AMD can be, for example, dry AMD.In a preferred embodiment, the AMD is dry AMD.

[0047] In another aspect, the present invention provides a method for treating or preventing diabetic retinopathy, comprising administering an AAV vector, cell or pharmaceutical composition of the present invention to a subject in need thereof.

[0048] The subject may, for example, have been diagnosed with or be at risk for developing AMD.

[0049] In a preferred embodiment, the AAV vector, cell or pharmaceutical composition is administered intraocularly.

[0050] In one embodiment, the AAV vector, cell or pharmaceutical composition is administered to the subject's eye by subretinal injection, direct retinal injection, suprachoroidal injection or intravitreal injection.

[0051] In a particularly preferred embodiment, the AAV vector, cell or pharmaceutical composition is administered to the subject's eye by subretinal injection.

[0052] In another aspect, the present invention provides the use of an AAV vector, cell or pharmaceutical composition of the invention for the manufacture of a medicament for the treatment or prevention of a complement-mediated eye disorder.

[0053] In one embodiment, the disorder is associated with overactivity of the complement C3b feedback cycle and / or underactivity of the C3b degradation cycle. In one embodiment, the disorder is age-related macular degeneration (AMD) or diabetic retinopathy. In a preferred embodiment, the disorder is AMD, preferably dry AMD.

[0054] In another aspect, the present invention provides the use of an AAV vector, cell or pharmaceutical composition of the present invention for the manufacture of a medicament for the treatment or prevention of age-related macular degeneration (AMD). In a preferred embodiment, the AMD is dry AMD.

[0055] In another aspect, the present invention provides the use of an AAV vector, cell or pharmaceutical composition of the invention for the manufacture of a medicament for the treatment or prevention of diabetic retinopathy. In one embodiment, the AAV vector of the invention does not comprise a hAAT promoter. In one embodiment, the AAV vector of the invention does not comprise the ApoR enhancer. In another embodiment, the AAV vector of the invention does not contain two ApoR enhancers.

[0056] In one embodiment, an AAV vector of the invention does not comprise an AAV2 genome and an AAV8 capsid protein, i.e., the AAV vector of the invention is not an AAV2 / 8 vector.

[0057] In one embodiment, the AAV vectors, cells or pharmaceutical compositions of the invention are not administered systemically, hi another embodiment, the AAV vectors, cells or pharmaceutical compositions of the invention are not administered intravenously. [Brief description of the drawings]

[0058] [Figure 1] FIG. 1 is a diagram illustrating the C3b feedback (amplification) and degradation (downregulation) cycle of the alternative pathway of vertebrate complement ("I"=factor I, "H"=factor H, "B"=factor B, and "D"=factor D). [Diagram 2] Figure 2 shows an agarose gel of restriction digests of CFI and CFIco. The 1752 bp band of CFI was excised and cloned into the pAAV-CBA-WPRE-bGHpA backbone. [Diagram 3] Figure 3 shows immunoblotting of CFI (Figure 3A) and GFP (Figure 3B). 3A: CFI appeared as a 70 kDa band (non-reduced) and was expressed in equal proportions after transfection of ARPE-19 with pAAV.CFI or pAAV.CFIco. CFI was not expressed after transfection with pAAV. 10% normal human serum (NHS) was used as a positive control for CFI immunoblotting. 3B: Transfection efficiency was analyzed by co-transfection of ARPE-19 cells with pCMV.GFP. GFP appeared as a 30 kDa band and the immunoblot confirmed that the cells were transfected with similar efficiency. [Figure 4]Figure 4 shows immunoblotting of CFI in the supernatants of virally transduced HEK-293 and ARPE-19 cell lines. 4A: Supernatants were loaded under non-reducing conditions and CFI was detected using a mouse monoclonal antibody against human CFI (OX21, Thermo Fisher Scientific) and a donkey anti-mouse IgG HRP-conjugated antibody (Abcam). CFI and CFIco were expressed in both cell lines. Transduction of cell lines with AAV.GFP served as a negative control, while 0.5 μg of plasma-purified human CFI (herein referred to as "CFIpl") (Comptech) served as a positive control. 4B: Supernatants were loaded under reducing conditions and CFI was detected using a goat antiserum against human CFI (Comptech) and a rabbit anti-goat IgG (whole molecule)-peroxidase antibody (Sigma). CFI appeared at 80 kDa (proenzyme), 50 kDa (processed; heavy chain) and 35 kDa (processed; light chain). AAV.GFP served as a negative control, while 0.5 μg of plasma purified human CFI (Comptech) and 10% normal human serum (referred to herein as "NHS") served as positive controls. CFI and CFIco were expressed in both cell lines. [Diagram 5]FIG. 5 shows representative results of a C3b cleavage assay. Lane 1 shows C3b incubated with CFH alone. Lane 2 shows C3b incubated with CFH and CFIpl. C3b is degraded by CFIpl to iC3b and C3dg. Lane 3 shows C3b incubated with CFH and supernatant from HEK-293 transduced with AAV.CFI. Lanes 4-5 show C3b incubated with CFH and CFI immunoprecipitated (indicated as "IP CFI") from ARPE-19 cells transduced with AAV.CFI (lane 4) or AAV.CFIco (lane 5). Lanes 6-7 show C3b incubated with CFH and CFI immunoprecipitated from HEK-293 transduced with AAV.CFI (lane 6) or AAV.CFIco (lane 7). [Figure 6] Figure 6 shows immunoblotting of secreted CFI from ARPE-19 cells cultured in transwells. The cells were not differentiated into hexagonal cells, but were cultured as a confluent monolayer of cells, and cell division was minimized by the addition of 1% serum medium. 6A: Supernatants from both compartments were loaded under non-reducing conditions, and Western blot analysis was performed using a mouse monoclonal against CFI (Ap = apical compartment and Bl = basolateral compartment). It is shown that CFI is expressed from a confluent monolayer of cells, and that secreted protein is detected in both compartments. 6B: Hoechst staining of nuclei was performed to confirm the presence of a monolayer of cells (staining was performed after harvesting the supernatant). [Figure 7]FIG. 7 shows CFI protein expression of pooled samples analyzed by immunoblotting. CFI is expressed at detectable levels from both AAV.CFI and AAV.CFIco at all doses. β-actin was loaded as a loading control. 7A: 40 μg of protein lysate was loaded under reducing conditions and CFI was detected using a polyclonal goat antiserum against human CFI. CFI is detected as 80 kDa (proenzyme), 50 kDa (processed; heavy chain) and 35 kDa (processed; light chain). These bands are consistent with the expected size of CFI, confirming the presence of processing, i.e., heavy and light chains. 7B: For lysate samples from eyes injected or non-injected with 109 gc / eye AAV.CFIco, the same amount of protein lysate was similarly loaded. CFI was detected using a mouse monoclonal against CFI (left, non-reduced gel) and a goat antiserum against CFI (right, reduced gel). In the non-reduced gel (left), CFI is detected as a 75 kDa band in the injected animals and no band is detected in the non-injected eyes. In the reduced gel (right), CFI appears as 80 kDa (proenzyme), 50 kDa (processed; heavy chain), and 35 kDa (processed; light chain). [Figure 8] FIG. 8 shows gene expression analysis by qPCR. [Figure 9] FIG. 9 shows the localization of hCFI in sham (A-C), AAV.CFI (D-F) and AAV.CFIco (G-H) injected eyes. Retinal sections were double labeled with fibronectin (A, D and G) and hCFI (B, E and H). Nuclei were stained with DAPI and overlaid (C, F and I). Scl: sclera, RPE: retinal pigment epithelium, OS: photoreceptor outer segment, IS: photoreceptor inner segment, OPL: outer plexiform layer, GCL: ganglion cell layer, NFL: nerve fiber layer, magnification: 20X, scale bar: 50 μm. [Figure 10]FIG. 10 shows localization of hCFI in sham (A-C) and AAV.CFI (D-F) injected eyes: RPE magnification is higher. Retinal sections were double labeled with fibronectin (A and D) and hCFI (B and E). Nuclei were stained with DAPI and overlaid (C and F). Scl: sclera, Bru: Bruch's membrane, Cho: choriocapillaris, RPE: retinal pigment epithelium, IPM: interphotoreceptor matrix. Magnification: 189X, Scale bar: 10 μm. Vesicular staining is indicated by arrows and RPE microvilli are indicated by asterisks at the lower edge of the RPE. [Figure 11] FIG. 11. Localization of hCFI in sham (A-C) and AAV.CFI (D-F) injected eyes: higher magnification of photoreceptor layer. Retinal sections were double labeled with fibronectin (A and D) and hCFI (B and E). Nuclei were stained with DAPI and shown overlaid (C and F). IPM: interphotoreceptor matrix, OS: outer segment, IS: inner segment, ONL: outer nuclear layer. Magnification: 189X, scale bar: 10 μm. [Figure 12] FIG. 12. Localization of hCFI in sham (A-C) and AAV.CFI (D-F) injected eyes: higher magnification of the outer plexiform layer (OPL). Retinal sections were double labeled with fibronectin (A and D) and hCFI (B and E). Nuclei were stained with DAPI and overlaid (C and F). ONL: outer nuclear layer, INL: inner nuclear layer. Magnification: 189X, Scale bar: 10 μm. Staining of horizontal cells is indicated by arrows. [Figure 13] FIG. 13. Localization of hCFI in sham (A-C) and AAV.CFI (D-F) injected eyes: higher magnification of ganglion cell layer (GCL). Retinal sections were double labeled with fibronectin (A and D) and hCFI (B and E). Nuclei were stained with DAPI and overlaid (C and F). IPL: inner plexiform layer, NFL: nerve fiber layer. Magnification: 189X, scale bar: 10 μm. [Figure 14]14 shows the localization of hCFI in sham (A-C), AAV.CFI (D-F) and AAV.CFIco (G-H) injected eyes. Retinal pigment epithelium whole tissue specimens were double stained for fibronectin (A, D and G) and hCFI (B, E and H). Magnification: 40X, Scale bar: 30 μm. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0059] complement system The complement system is an essential component of the humoral immune system and is involved in tissue inflammation, cell opsonization, and cell lysis. The complement system provides protection against microorganisms and mediates the clearance of exogenous and endogenous blood component debris from host tissues.

[0060] The complement system cascade consists of four activation pathways. All of the pathways ultimately end in the central cleavage of C3 factor and the generation of its active fragments C3a and C3b. C3a is an anaphylatoxin that induces various chemotactic and proinflammatory responses, such as recruitment of inflammatory cells and increased microvascular permeability, while C3b is involved in the opsonization of foreign surfaces covalently attached to C3b. Opsonization by activated C3 fragments (C3b and iC3b) serves three main functions: (i) clearance of blood component debris by phagocytes (e.g., macrophages or microglia) and stimulation of the adaptive immune system (B and T cells); (ii) amplification of complement activation via the formation of surface-bound C3 convertase; and (iii) assembly of C5 convertase.

[0061] The assembly of C5 convertase is involved in C5 cleavage, resulting in the formation of the cytolytic membrane attack complex (MAC) that can generate holes in the cell membrane, thereby facilitating cell lysis and the removal of unwanted cells. Through all of these activities, the innate complement cascade supports and promotes the function of downstream mechanisms of the immune system that protect the integrity of host tissues. Overall, activation of the complement pathway leads to proinflammatory responses, including MAC generation, which mediates cell lysis, release of chemokines to attract inflammatory cells to the site of injury, and increased capillary permeability to promote the migration of infiltrating leukocytes. Under physiological conditions, complement activation is effectively controlled by the coordinated action of soluble and membrane-bound complement regulatory molecules (CRMs). Soluble complement regulators, such as C1-inhibitor, anaphylatoxin inhibitor, C4b-binding protein (C4BP), complement factor H (CFH), complement factor I (CFI), clusterin, and vitronectin, limit the action of complement in human tissues at multiple sites in the cascade reaction. In addition, individual cells are protected from the attack of homologous complement by surface proteins, such as complement receptor 1 (CR1, CD35), membrane cofactor protein (CD46), and glycosylphosphatidylinositol-anchored proteins, such as decay-accelerating factor (CD55) or CD59 molecules. Notably, host cells and tissues that are not adequately protected from complement attack may suffer collateral cell lysis.

[0062] The present invention relates to the treatment or prevention of complement-mediated eye disorders.For example, complement-mediated disorders can be disorders that involve defects in metabolic pathway regulation, and in particular the overactivity of complement C3b feedback cycle and / or the underactivity of C3b degradation cycle.

[0063] In certain embodiments, prior to administration of the AAV vector, cell or pharmaceutical composition of the invention, the subject has a low (e.g., lower than normal) level of factor I activity, e.g., a low level of factor I activity in the eye and / or a low serum level of factor I activity. Subnormal levels of factor I activity can result from subnormal expression of normally functioning factor I, or at least partial (e.g., heterozygous) expression (at normal or subnormal levels) of a non-functional or sub-functional variant of factor I. (Such subjects may carry one or more copies of an AMD-associated SNP, e.g., the subject may be homozygous or heterozygous for one of the rare factor I variants described in more detail below). Thus, the subject may have a low (e.g., lower than normal) concentration of factor I in the eye and / or serum. For a human subject, a normal level of factor I activity (C3b-inactivating activity and iC3b-degrading activity) can be equivalent to the activity provided by 30-40 μg / mL of factor I in the serum of the subject. Thus, in subjects with low factor I activity, serum factor I activity may correspond to less than 30 μg / mL and more than 0 μg / mL of factor I, e.g., 0-20 or 0-10 μg / mL (which are ranges of factor I serum concentrations that may include subjects with low factor I concentrations).

[0064] Thus, the subject to be treated by the present invention may suffer from or be at risk of developing a complement-mediated eye disorder, such as AMD, more particularly dry AMD (e.g., characterized by geographic atrophy).For example, the subject may be predisposed to be homozygous or heterozygous for one or more SNPs associated with a complement-mediated disorder.

[0065] In some embodiments, the subject is at risk of developing AMD. For example, the subject may be prone to be homozygous or heterozygous for one or more SNPs associated with AMD, such as a rare mutation in factor I that typically leads to reduced serum factor I levels and is associated with advanced AMD (Kavanagh et al., Hum Mol Genet. 2015 Jul 1;24(13):3861-70). In particular, the subject may carry one or two copies of one or more of the following rare factor I variants: rs144082872 (encoding P50A); 4:110687847 (encoding P64L); rs141853578 (encoding G119R); 4:110685721 (encoding V152M); 4:110682846 (encoding G162D); 4:110682801 (encoding N177I); rs146444258 (encoding A240G); rs182078921 (encoding G287R); rs41278047 (encoding K441R); rs121964913 (encoding R474).

[0066] The invention may further include determining whether the subject is at risk for developing a complement-mediated disorder (e.g., AMD), e.g., by determining whether the subject is predisposed to be homozygous or heterozygous for one or more SNPs associated with a complement-mediated disorder (e.g., by determining whether the subject is predisposed to be homozygous or heterozygous for one or more of the rare factor I variants associated with AMD listed above).

[0067] Alternatively, the subject may have normal levels of endogenous factor I activity or concentration, e.g., in the eye and / or serum, and / or may not carry a rare mutant factor I allele.

[0068] In one embodiment, administration of the AAV vector, cell or pharmaceutical composition of the invention thereby increases the level of C3b-inactivating activity and iC3b-degrading activity in the eye of the subject. In another embodiment, administration of the AAV vector, cell or pharmaceutical composition of the invention thereby increases the level of C3b-inactivating activity and iC3b-degrading activity in the eye of the subject to a level above the normal level in the eye. More specifically, the level of C3b-inactivating activity and iC3b-degrading activity is increased in the RPE of the eye.

[0069] It will be understood that C3b-inactivating activity and iC3b-degrading activity in the subject following expression of an I factor or a fragment or derivative thereof from an AAV vector of the present invention may include C3b-inactivating activity and iC3b-degrading activity derived from the subject's endogenous I factor (i.e., the I factor of the subject that has not been produced by expression from an AAV vector), as well as C3b-inactivating activity and iC3b-degrading activity resulting from expression from an AAV vector of the present invention, such that the total level of C3b-inactivating activity and iC3b-degrading activity in the subject is greater than normal levels.

[0070] In certain embodiments, the level of C3b-inactivating activity and iC3b-degrading activity in the subject, eg, in the eye, is increased to a level at least 5%, 10%, 15%, 20%, or 25% above normal levels.

[0071] In another embodiment, the level of C3b-inactivating activity and iC3b-degrading activity in the subject, e.g., in the eye, is increased to a level that is up to twice normal levels, or up to 80%, 60%, 40% or 20% above normal levels.

[0072] For example, the level of C3b-inactivating activity and iC3b-degrading activity in said subject, e.g. in the eye, may be increased to a level that is 5-100%, 5-80%, 5-60%, 5-40%, 5-20%, 10-100%, 10-80%, 10-60%, 10-40%, 10-20%, 15-100%, 15-80%, 15-60%, 15-40%, 15-20%, 20-100%, 20-80%, 20-60%, 20-40%, 25-100%, 25-80%, 25-60% or 25-40% above normal levels.

[0073] In one embodiment, administration of an AAV vector, cell or pharmaceutical composition of the invention does not detectably increase the level of C3b-inactivating activity and iC3b-degrading activity in the plasma / serum of the subject. In another embodiment, administration of an AAV vector, cell or pharmaceutical composition of the invention does not detectably increase the level of C3b-inactivating activity and iC3b-degrading activity in the plasma / serum of the subject to a level higher than normal.

[0074] In the preceding paragraphs, unless clearly inappropriate, the terms factor I and C3b-inactivating activity and iC3b-degrading activity may be substituted with factor H and the ability to act as a cofactor for factor I-mediated cleavage of C3b and to increase the rate of dissociation of C3 and C5 convertases, respectively. In one embodiment, prior to administration of the AAV vector, cell or pharmaceutical composition of the invention, the subject has a low (e.g., lower than normal) level of factor H, e.g., a low level of factor H in the eye and / or a low serum level of factor H. For a human subject, a normal level of factor H may be about 200-500 μg / mL in the serum of the subject. Thus, in a subject with a low level of factor H, the level in serum may be less than 200 μg / mL and greater than 0 μg / mL, e.g., 0-100 μg / mL. Alternatively, the subject may have a normal level of endogenous factor H, e.g., in the eye and / or serum.

[0075] I factor Complement factor I (factor I, CFI), also known as C3b / C4b inactivating factor, is a protein that in humans is encoded by the CFI gene.

[0076] Factor I is a serine protease that circulates in a zymogen-like state (Roversi et al.; PNAS; 2011; 108(31):12839-12844) at a concentration of ~35 μg / mL (Nilsson et al.; Mol Immunol 2011, 48(14):1611-1620). The factor I protein is a heavily N-glycosylated heterodimer consisting of two polypeptide chains linked by a single disulfide bond. The heavy chain (50 kDa) contains an N-terminal region; a FI membrane attack complex (FIMAC) domain; a CD5-like-domain or a scavenger receptor cysteine-rich (SRCR) domain; two low density lipoprotein receptor (LDLr) domains; and a C-terminal region of unknown function (Roversi et al.; supra), a site of sequence diversity between species. The light chain (38 kDa) contains a serine protease (SP) domain with conserved catalytic residues (Goldberger et al.; J Biol Chem 1987, 262(21):10065-10071).

[0077] Factor I inactivates C3b by cleaving it into iC3b, C3d and C3d,g, and in a similar manner, C4b into C4c and C4d. To perform its function properly, factor I requires the presence of cofactor proteins, such as C4b-binding protein (C4BP), complement factor H (CFH), complement receptor 1 (CR1 / CD35) and membrane cofactor protein (MCP / CD46) (Degn et al.; Am J Hum Genet 2011, 88(6):689-705).

[0078] iC3b cannot associate with factor B and therefore cannot perpetuate amplification of the complement cascade or activation through the alternative pathway, therefore, once C3b is cleaved to iC3b, neither initiation of the alternative pathway nor activation of the terminal complement cascade occurs.

[0079] iC3b can provide proinflammatory effects by binding to and activating complement receptor 3 (CR3) (CD11b / CD18) on polymorphonuclear leukocytes (mainly neutrophils), NK cells, and mononuclear phagocytes such as macrophages.

[0080] Factor I can process iC3b to C3d,g through a protease activity that requires the cofactor CR1. C3d,g cannot bind to CR3. Because iC3b reacts with the complement receptor CR3, which is the primary mechanism by which complement activation causes inflammation, degradation of iC3b to C3d,g is essential to attenuate complement-induced inflammation (Lachmann (2009), Adv. Immunol., 104:115-149).

[0081] The unique ability of factor I to promote the cleavage of C3b to iC3b and accelerate the degradation of iC3b, combined with its relatively low concentration in human serum, makes C3b a particularly advantageous target in terms of affecting the amount that needs to be delivered for therapeutic effect.

[0082] In certain embodiments, the factor I polypeptide, or a fragment or derivative thereof, can cleave C3b into inactive degradation products, for example, the factor I polypeptide, or a fragment or derivative thereof, can be capable of cleaving C3b into iC3b.

[0083] In certain embodiments, the Factor I polypeptide or a fragment or derivative thereof can process iC3b to inactive degradation products, for example, the Factor I polypeptide or a fragment or derivative thereof may be capable of processing iC3b to C3d,g.

[0084] In a preferred embodiment, the Factor I polypeptide, or a fragment or derivative thereof, is capable of cleaving C3b to iC3b, and processing iC3b to C3d,g.

[0085] Fragments or derivatives of factor I may retain at least 50%, 60%, 70%, 80%, 90%, 95% or 100% of the C3b-inactivating activity and iC3b-degrading activity of native factor I. The C3b-inactivating activity and iC3b-degrading activity of fragments or derivatives of factor I and native factor I may be measured using any suitable method known to those skilled in the art. For example, the measurement of the proteolytic activity of factor I is described in Hsiung et al. (Biochem. J. (1982) 203, 293-298). Both the hemolytic and agglutination assays for FI activity are described in Lachmann PJ and Hobart MJ (1978) "Complement Technology" in Handbook of Experimental Immunology 3rd edition Ed DM Weir Blackwells Scientific Publications Chapter 5A p17. A more detailed description, including the proteolytic assay, is described by Harrison RA (1996) in "Weir's Handbook of Experimental Immunology" 5th Edition Eds; Herzenberg Leonore A'Weir DM, Herzenberg Leonard A and Blackwell C Blackwells Scientific Publications Chapter 75 36-37. The agglutination assay is very sensitive and can be used to both detect the initial (double) clip that converts fixed C3b to iC3b and acquires reactivity with conglutinin; as well as to detect the final clip to C3dg by starting from fixed iC3b and looking for a loss of reactivity with conglutinin. The hemolytic assay is used for the conversion of C3b to iC3b, and the proteolytic assay detects all of the clips.

[0086] In one embodiment, the factor I is human factor I.

[0087] One example of a human factor I protein is the human factor I protein having UniProtKB Accession No. P05156. This exemplary sequence is 583 amino acids in length (shown as SEQ ID NO:1), of which amino acids 1-18 form the signal sequence.

[0088] In one embodiment, the amino acid sequence of factor I is the sequence shown as SEQ ID NO: 1. In one embodiment, the amino acid sequence of factor I is the sequence shown as positions 19 to 583 of SEQ ID NO:1. JPEG2024156706000002.jpg11125JPEG2024156706000003.jpg46120 (Sequence Number 1)

[0089] In one embodiment, the amino acid sequence of factor I is the sequence shown as SEQ ID NO: 9, which corresponds to NCBI accession number NP_000195. In one embodiment, the amino acid sequence of factor I is the sequence shown as positions 19 to 583 of SEQ ID NO: 9. JPEG2024156706000004.jpg45147 (sequence number 9)

[0090] One example of a nucleotide sequence encoding factor I is the nucleotide sequence having NCBI accession number NM_000204. In one embodiment, the nucleotide sequence encoding factor I is the nucleotide sequence having NCBI accession number NM_000204.

[0091] In one embodiment, the nucleotide sequence encoding factor I is the nucleotide sequence shown as SEQ ID NO:2. JPEG2024156706000005.jpg68127JPEG2024156706000006.jpg41125 (Sequence Number 2)

[0092] The nucleotide sequences used in the present invention may be codon-optimized. Codon optimization has been previously described in WO 1999 / 041397 and WO 2001 / 079518. Different cells vary in their frequency of use of certain codons. This codon bias corresponds to a bias in the relative abundance of certain tRNAs in a cell type. Expression can be increased by altering the codons in the sequence and adjusting them to match the relative abundance of the corresponding tRNA. Similarly, expression can be decreased by deliberately selecting codons whose corresponding tRNAs are known to be rare in a particular cell type. Thus, an additional degree of translational control can be utilized.

[0093] In one embodiment, the nucleotide sequence encoding factor I is the nucleotide sequence shown as SEQ ID NO:8. JPEG2024156706000007.jpg103161 (sequence number 8)

[0094] The nucleotide sequence encoding the I factor or a fragment or derivative thereof may comprise, for example, a nucleotide sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 2 or 8, provided that the protein encoded by the nucleotide sequence substantially retains the functional activity of the protein represented by SEQ ID NO: 1 or 9.

[0095] The nucleotide encoding factor I or a fragment or derivative thereof may comprise, for example, a nucleotide sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence shown as positions 55 to 1752 of SEQ ID NO: 2 or 8, and in this case, the protein encoded by the nucleotide sequence substantially retains the functional activity of the protein shown in SEQ ID NO: 1 or 9.

[0096] A nucleotide sequence encoding factor I or a fragment or derivative thereof may, for example, encode an amino acid sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 1 or 9, provided that the amino acid sequence substantially retains the functional activity of the protein represented by SEQ ID NO: 1 or 9.

[0097] A nucleotide sequence encoding factor I or a fragment or derivative thereof may encode an amino acid sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence shown as positions 19 to 583 of SEQ ID NO: 1 or 9, and in this case, the amino acid sequence is considered to substantially retain the functional activity of the protein shown in SEQ ID NO: 1 or 9.

[0098] The advantage of the present invention is that factor I is particularly difficult to prepare in the form of purified protein.Therefore, the inventors have devised a method of modulating the complement system by administering factor I in the form of an AAV vector comprising a nucleotide sequence encoding factor I, for example to enable the treatment of age-related macular degeneration (AMD).The AAV vector may be administered to the site of interest, for example the eye, to enable the in situ translation of factor I polypeptide.

[0099] H factor Complement factor H (Factor H, CFH) is a complement regulatory protein.

[0100] The complement factor H is a large (155 kDa), soluble glycoprotein present in human plasma at typical concentrations of 200-300 μg / mL (Hakobyan et al.; 2008; 49(5):1983-90). The primary function of factor H is to regulate the alternative pathway of the complement system.

[0101] Factor H provides cofactor activity for factor I-mediated cleavage of C3b and also increases the rate of dissociation of the C3bBb complex (C3 convertase) and the (C3b)NBB complex (C5 convertase), thereby decreasing the activity of the alternative complement pathway.

[0102] Factor H is composed of 20 complement control protein (CCP) modules (also called short consensus repeats or sushi domains) linked to each other by short linkers (3-8 amino acid residues) and arranged in an extended row. Each of the CCP modules consists of about 60 amino acids disulfide-bonded by four cysteine ​​residues in a 1-3 2-4 configuration and a hydrophobic core built around an almost invariant tryptophan residue. The CCP modules are numbered 1-20 (from the N-terminus of the protein). CCPs 1-4 and CCPs 19-20 are involved in C3b, while CCPs 7 and CCPs 19-20 bind GAGs and sialic acids (Schmidt et al.; 2008; Journal of Immunology 181 (4):2610-9).

[0103] Gene therapy utilizing factor H has been shown to be able to ameliorate induced AMD-like pathology in mice (Cashman et al. (2015) J. Gene Med. 17:229-243). Mice were subretinally co-injected with (i) an adenoviral vector expressing complement component C3, previously shown to recapitulate many pathological features of human AMD; and (ii) an adenoviral vector expressing factor H. Compared to control animals receiving GFP instead of factor H, factor H-transduced mice showed a 91% reduction in endothelial cell proliferation and a 69% attenuation in RPE atrophy. Electroretinography showed improved retinal function in factor H-fed mice, and immunocytochemistry for rhodopsin and RPE65 was consistent with receptor and RPE rescue in such animals.

[0104] In certain embodiments, a factor H polypeptide, or a fragment or derivative thereof, can act as a cofactor for factor I-mediated cleavage of C3b. In certain embodiments, a factor H polypeptide, or a fragment or derivative thereof, can increase the rate of dissociation of C3 and C5 convertases.

[0105] In a preferred embodiment, the Factor H polypeptide, or a fragment or derivative thereof, acts as a cofactor for the Factor I-mediated cleavage of C3b and is capable of increasing the rate of dissociation of the C3 and C5 convertases.

[0106] In one embodiment, the Factor H is human Factor H.

[0107] An example of a human Factor H protein is the human Factor H protein having UniProtKB Accession No. P08603. This exemplary sequence is 1231 amino acids in length (shown as SEQ ID NO:3), of which amino acids 1-18 form the signal sequence.

[0108] In one embodiment, the amino acid sequence of factor H is the sequence shown as SEQ ID NO: 3. In one embodiment, the amino acid sequence of factor H is the sequence shown as positions 19 to 1231 of SEQ ID NO:3. JPEG2024156706000008.jpg104123 (sequence number 3)

[0109] One example of a nucleotide sequence encoding Factor H is the nucleotide sequence having NCBI Accession No. NM_000186. In one embodiment, the nucleotide sequence encoding Factor H is the nucleotide sequence having NCBI Accession No. NM_000186.

[0110] In one embodiment, the nucleotide sequence encoding Factor H is the nucleotide sequence shown as SEQ ID NO:4. JPEG2024156706000009.jpg69126JPEG2024156706000010.jpg151123 (Sequence Number 4)

[0111] A nucleotide sequence encoding Factor H or a fragment or derivative thereof may comprise, for example, a nucleotide sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:4, provided that the protein encoded by the nucleotide sequence substantially retains the functional activity of the protein represented by SEQ ID NO:3.

[0112] A nucleotide sequence encoding factor H or a fragment or derivative thereof may contain, for example, a nucleotide sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence shown as positions 55 to 3696 of SEQ ID NO: 4, in which case the protein encoded by the nucleotide sequence substantially retains the functional activity of the protein represented by SEQ ID NO: 3.

[0113] The nucleotide sequence encoding factor H of the present invention may encode an amino acid sequence having, for example, at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:3, provided that the amino acid sequence substantially retains the functional activity of the protein represented by SEQ ID NO:3.

[0114] The nucleotide sequence encoding factor H of the present invention may encode an amino acid sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence shown as positions 19 to 1231 of SEQ ID NO: 3, and in this case, the amino acid sequence is deemed to substantially retain the functional activity of the protein represented by SEQ ID NO: 3.

[0115] D factor Complement factor D (CFD) is involved in the alternative pathway of the complement system and functions by cleaving factor B to produce factors Bb and Ba.

[0116] Factor D is a member of the trypsin family of peptidases. All members of the chymotrypsin family of serine proteases have a very similar structure. In all cases, including factor D, there are two antiparallel β-barrel domains, each barrel containing six β-strands with the same pattern in all enzymes. The main difference in the backbone structure between factor D and other serine proteases of the chymotrypsin family is in the surface loops that connect the secondary structure elements.

[0117] The alternative complement activation cascade is initiated by spontaneous hydrolysis of C3, which is abundant in plasma. "Tickover" occurs when the thioester bond in C3 spontaneously breaks down to C3(H 2 O) formation.

[0118] This change in shape allows the binding of the plasma protein factor B, so that factor D can cleave it into Ba and Bb. Bb is C3(H 2 O) and remains as part of C3 (H 2 O)Bb. This complex is also known as fluid-phase C3 convertase. This convertase is produced in small amounts but is capable of cleaving multiple C3 proteins into C3a and C3b.

[0119] An AAV vector of the invention may comprise a nucleotide sequence encoding an anti-Factor D antibody.

[0120] The anti-Factor D antibody may bind to Factor D and reduce or prevent the functional activity of Factor D. For example, the anti-Factor D antibody may reduce or prevent binding of Factor D to Factor B and / or cleavage of Factor B by Factor D.

[0121] Suitable anti-Factor D antibodies are known in the art, including, but not limited to, lampalizumab.

[0122] Complement component 5 Complement component 5 (C5) is the fifth component of complement and plays an important role in inflammatory and cell killing processes. C5 consists of α and β polypeptide chains linked by disulfide bridges.

[0123] C5 is cleaved by the protease C5-convertase into complement component 5a (C5a) and C5b fragments. C5b is important in the later events of the complement cascade, whereas C5a acts as a highly inflammatory peptide. The usual source of C5 is hepatocytes, but its synthesis is also found in macrophages, which may lead to a local increase in C5a. C5a has chemotactic and anaphylatotoxic properties and is essential for innate immunity, but is also associated with adaptive immunity. Increased production of C5a is associated with a number of inflammatory diseases.

[0124] C5a is an anaphylatoxin that causes increased expression of adhesion molecules on the endothelium, contraction of smooth muscle, and increased vascular permeability. C5a des-Arg (lacking the C-terminal arginine) is a less potent anaphylatoxin. Both C5a and C5a des-Arg can induce mast cell degranulation, which releases the proinflammatory molecules histamine and TNF-α. C5a is also a potent chemoattractant that initiates the accumulation of complement and phagocytes at the site of infection or recruitment to lymph nodes. C5a plays an important role in increasing the migration and adhesion of neutrophils and monocytes to the vessel wall. Leukocytes are activated by upregulation of integrin avidity, lipoxygenase pathway, and arachidonic acid metabolism. C5a also modulates the balance between activating and inhibitory IgG Fc receptors on leukocytes, thereby enhancing autoimmune responses.

[0125] The AAV vector of the invention may comprise a nucleotide sequence encoding an anti-C5 antibody.

[0126] The anti-C5 antibodies may bind to C5 and prevent the cleavage of C5 into C5a and C5b.

[0127] Suitable anti-C5 antibodies are known in the art, including, but not limited to, eculizumab.

[0128] antibody Antibody refers to any portion of an antibody or a fragment thereof that retains the ability to bind to the same antigen target as the parent antibody.

[0129] The antibody may be a chimeric antibody, which may be produced by grafting an antibody variable domain from one species (e.g. mouse) onto an antibody constant domain from another species (e.g. human).

[0130] The antibody may be a full length classical antibody, for example, the antibody may be an IgG, IgM or IgA molecule.

[0131] The antibody may be a functional antibody fragment. Specific antibody fragments include, but are not limited to, (i) a Fab fragment consisting of the VL, VH, CL and CH1 domains, (ii) an Fd fragment consisting of the VH and CH1 domains, (iii) an Fv fragment consisting of the VL and VH domains of a single antibody, (iv) a dAb fragment consisting of a single variable domain, (v) an isolated CDR region, (vi) an F(ab')2 fragment, which is a bivalent fragment containing two linked Fab fragments, (vii) a single chain Fv molecule (scFv) in which the VH and VL domains are linked by a peptide linker that allows the two domains to associate and form an antigen-binding site, (viii) a bispecific single chain Fv dimer, and (ix) a "bispecific antibody" or "trispecific antibody", which is a multivalent or multispecific fragment constructed by genetic fusion. The antibody fragment may be modified. For example, the molecule may be stabilized by the incorporation of a disulfide bridge linking the VH and VL domains.

[0132] The antibodies described herein may be multispecific antibodies, and in particular bispecific antibodies, sometimes referred to as "bispecific antibodies". These are antibodies that bind to two (or more) different antigens. The antibodies may be minibodies. Minibodies are minimized antibody-like proteins that contain an scFv linked to a CH3 domain. In some cases, the scFv can be linked to an Fc region and may also include part or all of the hinge region.

[0133] The antibody may be a domain antibody (also called a single domain antibody or nanobody), which is an antibody fragment that contains a single monomeric single variable antibody domain. Examples of single domain antibodies include, but are not limited to, VHH fragments naturally found in camelids and VNAR fragments naturally found in cartilaginous fish. Single domain antibodies can also be generated by splitting the dimeric variable domain from a typical IgG molecule into monomers.

[0134] The antibody may be a synthetic antibody (also called an antibody mimic), including but not limited to Affibodies, DARPins, Anticalins, Avimers, Versabodies and Duocalins.

[0135] Age-related Macular Degeneration (AMD) The clinical progression of AMD is characterized by stages according to changes in the macula. Early AMD is characterized by drusen, which are accumulations of extracellular blood debris beneath the retina that appear as yellowish spots within the retina on clinical examination and fundus photography. Drusens are classified according to their size as small (<63 μm), medium (63–124 μm), and large (>124 μm). Drusens are also considered hard or soft depending on the appearance of their margins on ophthalmologic examination. Hard drusen have clearly defined margins, whereas soft drusen have unclear and fluid margins. The Age-Related Eye Disease Study (AREDS) Fundus Photography Severity Scale is one of the main classification systems used for the disease.

[0136] AMD is classified into "dry" and "wet" (exudative or neovascular) forms. Dry AMD is more common than wet AMD, but the dry form can progress to the wet form, and the two forms occur together in a significant number of cases. Dry AMD is typically characterized by progressive apoptosis of cells in the RPE layer, the overlying photoreceptor cells, and often the underlying choriocapillaris layer. Dense areas of RPE cell death accompanied by atrophy of the overlying photoreceptors are called geographic atrophy (GA). Patients with this form of AMD experience a slow and progressive deterioration of central vision.

[0137] Wet AMD is characterized by bleeding and / or fluid leakage from abnormal blood vessels growing from the RPE and choroidal vasculature (choriocapillaris) underlying the macula, which can contribute to sudden and disabling vision loss. It is estimated that most of this vision loss experienced by patients is due to such choroidal neovascularization (CNV) and its secondary complications.

[0138] Treatment or prevention of AMD as described herein may reduce or prevent the appearance of the AMD phenotypes described above. Preferably, treatment of AMD allows for the maintenance or improvement of visual function.

[0139] In some embodiments, treating or preventing AMD results in the prevention or reduction of the formation of geographic atrophy.In another embodiment, treating or preventing AMD results in the delay of the progression of geographic atrophy.For example, treating or preventing AMD results in at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% reduction in the increase of GA area over 12 months after administration to the treated eye of the subject, compared to the untreated eye over the same period.In another embodiment, treating or preventing AMD results in the treatment of geographic atrophy, for example, the reduction of the amount of geographic atrophy.

[0140] In one embodiment, treating or preventing AMD results in the prevention or reduction of the formation of drusen. In another embodiment, treating or preventing AMD results in the reduction of existing drusen, e.g., a reduction in the size and / or number of existing drusen.

[0141] In one embodiment, treating or preventing AMD results in the prevention or reduction of complement deposition, hi another embodiment, treating or preventing AMD results in the reduction of existing complement deposition.

[0142] In one embodiment, treating or preventing AMD results in improved or restored vision or visual acuity, hi another embodiment, treating or preventing AMD reduces the loss of vision or visual acuity.

[0143] In one embodiment, treating or preventing AMD results in improved or restored reading speed in a subject. In another embodiment, treating or preventing AMD reduces the decline in reading speed in a subject.

[0144] In certain embodiments, treating or preventing AMD results in the reduction or prevention of photoreceptor and / or retinal pigment epithelium (RPE) loss.

[0145] diabetic retinopathy Diabetic retinopathy is a condition characterized by damage to the blood vessels of the retina caused by the high blood sugar levels associated with diabetes. If left untreated, diabetic retinopathy can lead to blindness.

[0146] Although subjects with mild diabetic retinopathy may have good vision, two types of diabetic retinopathy, diabetic macular edema (DMO) and proliferative diabetic retinopathy (PDR), can threaten a subject's vision.

[0147] Diabetic macular edema is characterized by leakage of fluid from damaged blood vessels at the back of the eye. The fluid accumulates in the macula, causing swelling and blurred vision. Over time, this can lead to poor central vision and impaired ability to read or drive. Side vision usually remains normal.

[0148] Proliferative diabetic retinopathy is characterized by the blockage of retinal blood vessels, which leads to the growth of abnormal, fragile blood vessels on the surface of the retina, which can result in bleeding into the eye, scarring, and permanent loss of vision due to retinal detachment.

[0149] Eye structure The medicaments disclosed herein may be delivered to the eye of a mammal, preferably a human, for the treatment or prevention of age-related macular degeneration (AMD).

[0150] Those skilled in the treatment of eye disorders will have a detailed and thorough understanding of the structure of the eye, however, the following structures are described which are particularly relevant to the present invention.

[0151] retina The retina is a multi-layered membrane that lines the posterior chamber of the eye and detects images of the visual world that are transmitted to the brain via the optic nerve. From inside to outside the eye, the retina includes the neurosensory retina and the retinal pigment epithelium layer, together with the choroid layer outside the retinal pigment epithelium.

[0152] Neurosensory retina and photoreceptor cells The neurosensory retina contains the photoreceptor cells that directly sense light. It contains the following layers: the inner limiting membrane (ILM); the nerve fiber layer; the ganglion cell layer; the inner plexiform layer; the inner nuclear layer; the outer plexiform layer; the outer nuclear layer (photoreceptor nuclei); the outer limiting membrane (ELM); and the photoreceptors (the inner and outer segments of rods and cones).

[0153] Those skilled in the art will have a detailed understanding of photoreceptor cells. In simple terms, photoreceptor cells are specialized neurons located in the retina that convert light into biological signals. Photoreceptor cells include rod cells and cone cells, which are distributed differently in the retina.

[0154] Rod cells are mainly distributed in the outer part of the retina. They are highly sensitive and provide vision at low light levels. On average, there are about 125 million cone cells in a normal human retina.

[0155] Cones are found throughout the retina, but are highly concentrated in the fovea, a depression in the neurosensory retina responsible for high-resolution central vision. Cones are less sensitive than rods. On average, there are about 6-7 million cones in a normal human retina.

[0156] retinal pigment epithelium The retinal pigment epithelium (RPE) is a pigmented layer of cells located just outside the neurosensory retina. The RPE serves many functions, including transporting nutrients and other substances to photoreceptor cells and absorbing scattered light to improve vision.

[0157] choroid The choroid is a vascular membrane located between the RPE and the outer sclera of the eye. The choroid's vasculature allows the supply of oxygen and nutrients to the retina.

[0158] Adeno-associated virus (AAV) vectors In one aspect, the invention provides an AAV vector comprising a nucleotide sequence encoding factor I, or a fragment or derivative thereof, and / or factor H, or a fragment or derivative thereof.

[0159] Preferably, the AAV vector is in the form of an AAV particle.

[0160] Methods for preparing and modifying viral vectors and viral vector particles, such as those derived from AAV, are well known in the art.

[0161] The AAV vector may comprise an AAV genome or a fragment or derivative thereof.

[0162] AAV genome is a polynucleotide sequence that encodes the functions required for the production of AAV particles.These functions include those that operate in the replication and packaging cycle of AAV in host cells, such as the encapsidation of AAV genome into AAV particles.Naturally occurring AAV is replication-defective and depends on the provision of in trans helper functions for the completion of replication and packaging cycles.Therefore, the AAV genome of the AAV vector of the present invention is typically replication-defective.

[0163] The AAV genome may be in single-stranded form, either positive or negative sense, or in double-stranded form, the use of the double-stranded form allowing bypassing of the DNA replication step in the target cell and thus facilitating expression of the transgene.

[0164] The AAV genome may be from any naturally occurring serotype, isolate or clade of AAV.Thus, the AAV genome may be the whole genome of a naturally occurring AAV.As known to those skilled in the art, naturally occurring AAV can be classified according to various biological systems.

[0165] Generally, AAV is referred to in terms of their serotype.Serotype corresponds to the variant subspecies of AAV, and this variant subspecies has a unique reactivity that can be used to distinguish it from other variant subspecies by its capsid surface antigen expression profile.Typically, the virus with a certain AAV serotype does not cross-react effectively with the neutralizing antibody specific for any other AAV serotype.

[0166] AAV serotypes include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 and AAV11, as well as recombinant serotypes, such as Rec2 and Rec3, which have recently been identified from primate brain. Any of these AAV serotypes can be used in the present invention. Thus, in one embodiment of the present invention, the AAV vector particle is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rec2 or Rec3 AAV vector particle.

[0167] In certain embodiments, the AAV may be an AAV1, AAV2, AAV5, AAV7, AAV8 or AAV8 serotype.

[0168] In one embodiment, the AAV may be of the AAV2 or AAV8 serotype.

[0169] The capsid protein may be a mutant capsid protein as disclosed in WO 2008 / 124724, which is incorporated herein by reference.

[0170] In one embodiment, the AAV vector comprises an AAV8 capsid with a Y733F mutation.

[0171] A review of AAV serotypes can be found in Choi et al. (2005) Curr. Gene Ther. 5:299-310 and Wu et al. (2006) Molecular Therapy 14:316-27. The sequences of AAV genomes, or elements of the AAV genome including ITR sequences, rep or cap genes, for use in the present invention may be referenced to the following accession numbers for AAV complete genome sequences: Adeno-associated virus 1 NC_002077, AF063497; Adeno-associated virus 2 NC_001401; Adeno-associated virus 3 NC_001729; Adeno-associated virus 3B NC_001863; Adeno-associated virus 4 NC_001829; Adeno-associated virus 5 Y18065, AF085716; Adeno-associated virus 6 NC_001862; Avian AAV ATCC VR-865 AY186198, AY629583, NC_004828; Avian AAV strain DA-1 NC_006263, AY629583; Bovine AAV It may be derived from NC_005889, AY388617.

[0172] AAVs may also be referred to in terms of clades or clones, which refer to the phylogenetic relationships of naturally occurring AAVs and typically refer to phylogenetic groups of AAVs that can be traced back to a common ancestor and include all its descendants. Additionally, AAVs may also be referred to in terms of specific isolates, i.e., genetic isolates of specific AAVs found in nature. The term genetic isolate describes a population of AAVs that has undergone limited genetic mixing with other naturally occurring AAVs, thereby defining a population that is recognizably distinct at the genetic level.

[0173] Those skilled in the art can select the appropriate serotype, clade, clone or isolate of AAV for use in the present invention based on their common general knowledge. For example, AAV5 capsid has been shown to efficiently transduce primate cone photoreceptors, as evidenced by the successful correction of inherited color blindness (Mancuso et al. (2009) Nature 461:784-7).

[0174] The AAV serotype determines the tissue specificity of infection (or tropism) of the AAV virus. Thus, the AAV serotype suitable for use in the AAV administered to a patient according to the present invention is one that has a natural tropism for target cells in the eye or has a high infection efficiency of target cells in the eye. In one embodiment, the AAV serotype for use in the present invention transduces cells of the neurosensory retina, retinitis pigmentosa and / or choroid.

[0175] Typically, the AAV genome of a naturally occurring serotype, isolate or clade of AAV comprises at least one inverted terminal repeat (ITR). The ITR sequence acts in cis to provide a functional origin of replication, allowing integration and excision of the vector from the genome of the cell. In a preferred embodiment, one or more ITR sequences are adjacent to a nucleotide sequence encoding factor I and / or factor H (or a fragment or derivative thereof). The AAV genome typically also comprises packaging genes, such as the rep and / or cap genes, which encode the packaging functions of the AAV particle. The rep gene encodes one or more of the proteins Rep78, Rep68, Rep52 and Rep40 or mutants thereof. The cap gene encodes one or more capsid proteins, such as VP1, VP2 and VP3 or mutants thereof. These proteins constitute the capsid of the AAV particle. Capsid mutants are discussed below.

[0176] A promoter is operably linked to each of the packaging genes. Specific examples of such promoters include the p5, p19 and p40 promoters (Laughlin et al. (1979) Proc. Natl. Acad. Sci. USA 76:5567-5571). For example, the p5 and p19 promoters are typically used to express the rep gene, while the p40 promoter is typically used to express the cap gene.

[0177] As discussed above, the AAV genome used in the AAV vector of the present invention may therefore be the entire genome of a naturally occurring AAV. For example, AAV vectors or vector particles may be prepared in vitro by using vectors that contain the entire AAV genome. However, although such vectors may in principle be administered to patients, this is rarely done in practice. Preferably, the AAV genome is derivatized for administration to patients. Such derivatization is standard in the art, and the present invention encompasses the use of any known derivatives of the AAV genome, and derivatives that may be made by applying techniques known in the art. Derivatization of AAV genomes and AAV capsids is reviewed in Coura and Nardi (2007) Virology Journal 4:99, and Choi et al., and Wu et al. (supra).

[0178] Derivatives of AAV genome include any truncated or modified form of AAV genome that allows expression of transgene from the AAV vector of the present invention in vivo.Typically, AAV genome can be significantly truncated to contain minimal viral sequence but retain the above functions.This is preferred for safety reasons, reducing the risk of vector recombination with wild-type virus and avoiding the induction of cellular immune response due to the presence of viral gene protein in target cells.

[0179] Typically, the derivative comprises at least one inverted terminal repeat (ITR), preferably two or more ITRs, for example, two ITRs or more. One or more of the ITRs may be derived from AAV genomes with different serotypes, or may be chimeric or mutant ITRs. A preferred mutant ITR is one that has trs (terminal resolution site) deletion. This deletion allows for continued replication of the genome to create a single-stranded genome containing both coding and complementary sequences, i.e., a self-complementary AAV genome. This allows for avoidance of DNA replication in target cells, and therefore allows for accelerated transgene expression.

[0180] The one or more ITRs are preferably flanked on both sides by the nucleotide sequence encoding factor I and / or factor H (or a fragment or derivative thereof). The inclusion of one or more ITRs preferably promotes the formation of concatemers of the vectors of the invention in the nucleus of the host cell, e.g., after conversion of the single-stranded vector DNA to double-stranded DNA by the action of a host cell DNA polymerase. The formation of such episomal concatemers protects the vector construct during the life of the host cell, thereby allowing sustained expression of the transgene in vivo.

[0181] In a preferred embodiment, the ITR elements are the only sequences that are retained from the native AAV genome in the derivative.Thus, the derivative preferably does not contain the rep and / or cap genes of the native genome and any other sequences of the native genome.This is preferred for the reasons described above and also to reduce the possibility of the vector integrating into the host cell genome.In addition, the size of the AAV genome can be reduced to allow more flexibility in integrating other sequence elements (e.g., regulatory elements) into the vector in addition to the transgene.

[0182] Thus, the following portions may be removed in the derivatives of the invention: one inverted terminal repeat (ITR) sequence, the replication (rep) and the capsid (cap) genes. However, in some embodiments, the derivatives may further comprise one or more of the rep and / or cap genes or other viral sequences of the AAV genome. Naturally occurring AAV integrates at a high frequency into a specific site on human chromosome 19, and also shows a negligible frequency of random integration, such that retention of the integration capacity of the vector may be acceptable in a therapeutic setting.

[0183] Where the derivatives include capsid proteins, i.e., VP1, VP2 and / or VP3, the derivatives may be chimeric, shuffled or capsid-modified derivatives of one or more naturally occurring AAV. In particular, the invention encompasses the provision of capsid protein sequences from different serotypes, clades, clones or isolates of AAV within the same vector (i.e., pseudotyped vectors).

[0184] Chimeric, shuffled or capsid modified derivatives are typically selected to provide one or more desired functionalities to the AAV vector. Thus, these derivatives may show improved efficiency of gene delivery, reduced immunogenicity (humoral or cellular), altered tropism range and / or improved targeting of specific cell types compared to AAV vectors that contain naturally occurring AAV genomes, such as the AAV genome of AAV2. Improved efficiency of gene delivery may be achieved by improved receptor or co-receptor binding at the cell surface, improved internalization, improved intracellular and nuclear transport, improved uncoating of viral particles and improved conversion of single-stranded genome to double-stranded form. Improved efficiency may also be related to altered tropism range or targeting of specific cell populations, such that the vector dose is not diluted by administration to tissues that do not require it.

[0185] Chimeric capsid proteins include those produced by recombination between two or more capsid coding sequences of naturally occurring AAV serotypes. This may be done, for example, by marker rescue methods, in which a non-infectious capsid sequence of one serotype is co-transfected with a capsid sequence of a different serotype, and directed selection is used to select for capsid sequences with desired properties. The capsid sequence of the different serotype can be altered in cells by homologous recombination to produce novel chimeric capsid proteins.

[0186] Chimeric capsid proteins also include those created by manipulation of capsid protein sequences to transfer particular capsid protein domains, surface loops, or particular amino acid residues between two or more capsid proteins, for example between two or more capsid proteins of different serotypes.

[0187] Shuffled or chimeric capsid proteins can also be generated by DNA shuffling or error-prone PCR.Hybrid AAV capsid genes can be generated by randomly fragmenting the sequences of related AAV genes, such as sequences encoding capsid proteins of multiple different serotypes, and then reconstituting the fragments in a self-priming polymerase reaction that can also cross over in regions of sequence homology.The hybrid AAV gene library generated by shuffling the capsid genes of several serotypes in this way can be screened to identify viral clones with desired functionality.Similarly, error-prone PCR can be used to randomly mutate AAV capsid genes to generate a diverse library of mutants that can then be selected for desired properties.

[0188] The capsid gene sequence may also be genetically modified to introduce specific deletions, substitutions or insertions with respect to the native wild-type sequence. In particular, the capsid gene may be modified by the insertion of a sequence of an unrelated protein or peptide within the open reading frame of the capsid coding sequence or at the N- and / or C-terminus of the capsid coding sequence.

[0189] The unrelated protein or peptide may advantageously act as a ligand for a particular cell type, thereby providing improved binding to target cells or improving the specificity of targeting of the vector to a particular cell population. One example is the use of RGD peptides to inhibit uptake into the retinal pigment epithelium, thereby enhancing transduction of peripheral retinal tissues (Cronin et al. (2008) ARVO Abstract:D1048). The unrelated protein may also be one that facilitates purification of the viral particles as part of the production process, i.e. an epitope or affinity tag. The site of insertion is typically selected so as not to interfere with other functions of the viral particle, e.g. internalization, transport of the viral particle. Those skilled in the art can identify suitable sites for insertion based on their common general knowledge. Particular sites are disclosed in Choi et al. (supra).

[0190] The invention further encompasses the provision of sequences of the AAV genome in an order and arrangement different from that of the native AAV genome. The invention also encompasses the replacement of one or more AAV sequences or genes with sequences from another virus or with chimeric genes consisting of sequences from two or more viruses. Such chimeric genes may consist of sequences from two or more related viral proteins of different viral species.

[0191] An AAV vector of the invention may take the form of a nucleotide sequence that includes the AAV genome or a derivative thereof and sequences encoding the Factor I and / or Factor H transgenes or derivatives thereof.

[0192] The AAV particles of the present invention include trans-encapsidated forms, in which the AAV genome or derivatives with ITRs of one serotype are packaged in the capsid of a different serotype.The AAV particles of the present invention also include mosaic forms, in which a mixture of unmodified capsid proteins from two or more different serotypes constitutes the capsid of the virus.The AAV particles also include chemically modified forms that carry ligands adsorbed on the capsid surface.For example, such ligands can include antibodies for targeting specific cell surface receptors.

[0193] Thus, for example, AAV particles of the present invention include those having an AAV2 genome and AAV2 capsid protein (AAV2 / 2), those having an AAV2 genome and AAV5 capsid protein (AAV2 / 5), and those having an AAV2 genome and AAV8 capsid protein (AAV2 / 8), as well as those having AAV2 genomes and capsid proteins of two or more serotypes.

[0194] The AAV vector may contain multiple copies (eg, 2, 3, etc.) of the nucleotide sequences referred to herein.

[0195] Promoters and Regulatory Sequences The AAV vector of the present invention may also comprise elements that allow for the expression of the I factor and / or H factor transgene (or a fragment or derivative thereof) in vitro or in vivo. These may be referred to as expression control sequences. Thus, the AAV vector typically comprises an expression control sequence (e.g., including a promoter sequence) operably linked to the nucleotide sequence encoding the transgene.

[0196] Any suitable promoter may be used, and its selection can be easily made by one skilled in the art. The promoter sequence may be constitutively active (i.e. operable in any host cell background) or may be active only in a specific host cell environment, resulting in targeted expression of the transgene in a specific cell type (e.g. tissue-specific promoter). The promoter may also show inducible expression in response to the presence of another factor, e.g. a factor present in the host cell. In any case, when the vector is administered for therapy, it is preferred that the promoter is functional in the target cell background.

[0197] In some embodiments, it is preferred that the promoter exhibits retinal cell-specific expression, so that the transgene is expressed only in a population of retinal cells, and thus expression from the promoter may be retinal cell-specific, for example restricted to cells of the neurosensory retina and the retinal pigment epithelium.

[0198] A suitable promoter that is not retinal cell specific includes the chicken beta actin (CBA) promoter, optionally in combination with the cytomegalovirus (CMV) enhancer element. An example of a promoter for use in the present invention is the CAG promoter, such as the promoter used in the rAVE expression cassette (GeneDetect.com). A further example of a promoter for use in the present invention is the following sequence: JPEG2024156706000011.jpg9155JPEG2024156706000012.jpg58153(Sequence Number 5) has.

[0199] In one embodiment, the AAV vector comprises a promoter having the nucleotide sequence of SEQ ID NO: 5. In another embodiment, the AAV vector comprises a promoter having a nucleotide sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 5, wherein the nucleotide sequence substantially retains the functional activity of the promoter represented by SEQ ID NO: 5.

[0200] Examples of promoters based on human sequences that direct retina-specific gene expression include rhodopsin kinase for rods and cones (Allocca et al. (2007) J. Virol. 81:11372-80), PR2.1 for cones only (Mancuso et al. (2009) Nature 461:784-7), and / or RPE65 for the retinal pigment epithelium (Bainbridge et al. (2008) N. Engl. J. Med. 358:2231-9) or VMD2 (Esumi et al. (2004) J. Biol. Chem. 279:19064-73).

[0201] The AAV vector of the present invention may also comprise one or more additional regulatory sequences that may act pre- or post-transcriptionally. The regulatory sequence may be part of the natural transgene locus or a heterologous regulatory sequence. The AAV vector of the present invention may comprise a part of the 5'-UTR or 3'-UTR derived from the natural transgene transcript.

[0202] A regulatory sequence is any sequence that acts to facilitate the expression of a transgene, i.e. to increase the expression of the transcript, to improve the nuclear export of the mRNA, or to enhance its stability. Such regulatory sequences include, for example, enhancer elements, post-transcriptional regulatory elements, and polyadenylation sites. A suitable polyadenylation site is the bovine growth hormone polyA signal, which may be as follows: JPEG2024156706000013.jpg21156 (sequence number 6)

[0203] In one embodiment, the AAV vector comprises a polyadenylation site having the nucleotide sequence of SEQ ID NO: 6. In another embodiment, the AAV vector comprises a polyadenylation site having a nucleotide sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 6, wherein the nucleotide sequence substantially retains the functional activity of the polyadenylation site represented by SEQ ID NO: 6.

[0204] In the context of the AAV vectors of the invention, such regulatory sequences are cis-acting, however, the invention also encompasses the use of trans-acting regulatory sequences located on additional genetic constructs.

[0205] A preferred post-transcriptional regulatory element for use in the AAV vectors of the invention is the Woodchuck Hepatitis Post-transcriptional Regulatory Element (WPRE) or a variant thereof. An illustrative example of the sequence of the WPRE is shown below: JPEG2024156706000014.jpg40153 (sequence number 7)

[0206] In one embodiment, the AAV vector comprises a post-transcriptional regulatory element having a nucleotide sequence of SEQ ID NO: 7. In another embodiment, the AAV vector comprises a post-transcriptional regulatory element having a nucleotide sequence having at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 7, wherein the nucleotide sequence substantially retains the functional activity of the post-transcriptional regulatory element represented by SEQ ID NO: 7.

[0207] The present invention encompasses the use of any variant sequence of the WPRE that increases transgene expression compared to an AAV vector lacking the WPRE. Preferably, the variant sequence exhibits at least 70% identity over its entire sequence to SEQ ID NO:7, more preferably 75%, 80%, 85%, 90%, and more preferably at least 95%, 96%, 97%, 98% or 99% identity over its entire sequence to SEQ ID NO:7.

[0208] Another regulatory sequence that may be used in the AAV vectors of the invention is the scaffold attachment region (SAR). Additional regulatory sequences may be readily selected by one of skill in the art.

[0209] Method of administration In a preferred embodiment, the AAV vector is administered intraocularly.

[0210] The term "intraocular" refers to the inside of the eye, and thus, intraocular administration relates to administration to the inside of the eye of a subject.

[0211] In one embodiment of the invention, the AAV vector is administered to the subject's eye by subretinal, direct retinal, suprachoroidal or intravitreal injection, which in one embodiment is performed robotically.

[0212] The amount of the pharmaceutical composition to be injected may be, for example, about 10 to 500 μL, for example, about 50 to 500, 100 to 500, 200 to 500, 300 to 500, 400 to 500, 50 to 250, 100 to 250, 200 to 250, or 50 to 150 μL. The amount may be, for example, about 10, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 μL. Preferably, the amount of the pharmaceutical composition to be injected is 100 μL.

[0213] Those skilled in the art will be familiar with and able to successfully perform subretinal, direct retinal, suprachoroidal or intravitreal injections, respectively.

[0214] Preferably, the AAV vector is administered by subretinal injection.

[0215] In one embodiment, the AAV vector or a pharmaceutical composition comprising the AAV vector is administered only once or at most twice during the life of the subject.

[0216] subretinal injection Subretinal injection is injection into the subretinal space, i.e., beneath the neurosensory retina. During subretinal injection, the injected material is directed toward the layers of photoreceptor cells and the retinal pigment epithelium (RPE), forming a space between these layers.

[0217] If the injection is performed through a small retinal incision, it may cause retinal detachment, the detached raised layer of the retina created by the injected material being called a "bleb."

[0218] The hole created by the subretinal injection must be small enough that the injected solution does not flow back significantly into the vitreous cavity after administration. Such backflow would be particularly problematic when injecting drugs, as it would divert the effect of the drug from the target zone. Preferably, the injection creates a self-closing injection hole in the neurosensory retina, i.e., when the injection needle is removed, the hole created by the needle closes again, so that only a small amount or substantially no injected substance is released through the hole.

[0219] To facilitate this process, specialized subretinal injection needles are commercially available (e.g., DORC 41G Teflon subretinal injection needle, Dutch Ophthalmic Research Center International BV, Zuidland, The Netherlands). These are needles designed to perform subretinal injections.

[0220] Unless damage to the retina occurs during injection, and as long as a sufficiently thin needle is used, virtually all of the injected material remains localized between the detached neurosensory retina and the RPE at the site of focal retinal detachment (i.e., does not flow back into the vitreous cavity). In fact, the typical short-term survival of the bleb indicates that there is usually little outflow of injected material into the vitreous. The bleb may disappear over a longer period of time as the injected material is absorbed.

[0221] Visualization of the eye, and particularly the retina, may be performed pre-operatively, for example using optical coherence tomography.

[0222] The amount of the pharmaceutical composition to be injected may be, for example, about 10 to 500 μL, for example, about 50 to 500, 100 to 500, 200 to 500, 300 to 500, 400 to 500, 50 to 250, 100 to 250, 200 to 250 or 50 to 150 μL. The amount may be, for example, about 10, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 μL. Preferably, the amount of the pharmaceutical composition to be injected is 100 μL. A larger amount may increase the risk of pulling the retina, but a smaller amount may make it difficult to see.

[0223] Two-step subretinal injection The vector of the present invention may be delivered with increased precision and safety by using a two-step method in which a localized retinal detachment is created by subretinal injection of a first solution, which does not contain the vector. A second subretinal injection is then used to deliver a medicament containing the vector into the subretinal fluid of the bleb created by the first subretinal injection. Since the injection that delivers the medicament is not used to detach the retina, a specific amount of solution may be injected in this second step.

[0224] In one embodiment of the invention, the subretinal injection of the vector comprises the steps of (a) and (b): (a) administering to the subject by subretinal injection a solution in an amount effective to at least partially detach the retina to form a subretinal bleb, wherein the solution does not contain the vector; and (b) administering a pharmaceutical composition into the bleb formed by step (a) by subretinal injection, wherein the pharmaceutical composition comprises the vector; Includes.

[0225] The amount of solution injected in step (a) to at least partially detach the retina may be, for example, about 10-1000 μL, such as about 50-1000, 100-1000, 250-1000, 500-1000, 10-500, 50-500, 100-500, 250-500 μL, for example, about 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 μL.

[0226] The amount of the pharmaceutical composition injected in step (b) may be, for example, about 10 to 500 μL, for example, about 50 to 500, 100 to 500, 200 to 500, 300 to 500, 400 to 500, 50 to 250, 100 to 250, 200 to 250 or 50 to 150 μL. The amount may be, for example, about 10, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 μL. Preferably, the amount of the pharmaceutical composition injected in step (b) is 100 μL. A larger amount may increase the risk of pulling the retina, but a smaller amount may make it difficult to see.

[0227] The drug-free solution (i.e., the "solution" of step (a)) may be prepared similarly to the drug-free solution, as described below. A suitable drug-free solution is a buffered saline solution (BSS) or similar buffer that is compatible with the pH and osmolality of the subretinal space.

[0228] Intraoperative visualization of the retina Under certain circumstances, such as in the late stages of retinal degeneration, it is difficult to see the retina because it is thin and transparent, making it difficult to see the background of the destroyed and highly pigmented epithelium on which it rests.The use of blue vital dyes (e.g. Brilliant Peel®, Geuder; MembraneBlue-Dual®, Dorc) may facilitate the identification of the retinal hole created for the retinal detachment procedure (i.e., step (a) of the two-step subretinal injection method of the present invention), so that the medicine can be administered through the same hole without the risk of reflux into the vitreous cavity.

[0229] The use of blue vital dye will similarly identify any areas of the retina where a thickened internal limiting membrane or preretinal membrane is present, as injection through any of these structures would preclude skilled access to the subretinal space. Furthermore, contraction of any of these structures in the immediate postoperative period can cause traction of the retinal injection hole, which can lead to reflux of medication into the vitreous cavity.

[0230] suprachoroidal injection The vectors of the invention may be delivered to the suprachoroidal space using an ab externo approach using a microcatheter (see, e.g., Peden et al. (2011) PLoS One 6(2):e17140). In this method, a pericorneal incision of the limbal conjunctiva is performed to expose the bare sclera, followed by a sclerotomy to expose the bare choroid. A microcatheter (e.g., an iTrack 250A from iScience Interventional, optionally connected to an illumination device such as an iLumin laser-diode-based microillumination device (iScience Interventional)) is inserted into the suprachoroidal space and advanced posteriorly toward the optic nerve head. After manipulation of the microcatheter tip to the desired location, injection of the vector forms a bleb in the retina and choroid.

[0231] Thus, in one embodiment, the vector is delivered to the suprachoroid by a method comprising: (i) inserting a microcatheter into the suprachoroidal space; (ii) advancing the microcatheter into the space until its tip is in close proximity to the diseased area of ​​the retina; and (iii) injecting the vector from the microcatheter tip to create a bleb.

[0232] In some embodiments, the administration procedure is performed directly by the robot.

[0233] Pharmaceutical Compositions and Infusion Solutions The medicaments of the present invention, such as AAV vectors, may be formulated into pharmaceutical compositions. These compositions may contain, in addition to the medicament, pharma- ceutically acceptable carriers, diluents, excipients, buffers, stabilizers, or other substances known in the art. Such substances should be non-toxic and should not interfere with the effect of the active ingredient. The exact nature of the carrier or other substances can be determined by the skilled artisan depending on the route of administration, such as subretinal injection, direct retinal injection, suprachoroidal injection, or intravitreal injection.

[0234] Said pharmaceutical composition is typically in liquid form.Liquid pharmaceutical composition usually comprises liquid carrier, for example, water, petroleum, animal or vegetable oil, mineral oil or synthetic oil.Saline, magnesium chloride, dextrose or other sugar solution, or glycols, for example, ethylene glycol, propylene glycol or polyethylene glycol, may be included.Optionally, surfactant, for example, pluronic acid (PF68) 0.001%, may be used.

[0235] For injection at the affected site, the active ingredient may be in the form of an aqueous solution that is pyrogen-free and has appropriate pH, isotonicity and stability.Those skilled in the art can prepare suitable solutions by using isotonic solvents such as sodium chloride injection, Ringer's solution or lactated Ringer's solution.Preservatives, stabilizers, buffers, antioxidants and / or other additives may be included as necessary.

[0236] For delayed release, the pharmaceutical agent may be included in a pharmaceutical composition formulated for sustained release, such as in microcapsules formed from biocompatible polymers or liposome carrier systems by methods known in the art.

[0237] Treatment methods In the context of the present invention, reference to prevention is more generally associated with prophylactic treatment, although it will be understood that all references herein to treatment include curative, palliative and preventative treatment, which may also include arresting the progression of the severity of the disease.

[0238] The treatment of mammals, and especially humans, is preferred, although both human and animal treatments are within the scope of the present invention.

[0239] Variants, derivatives, analogues, homologues and fragments In addition to the specific proteins and nucleotides described herein, the present invention also encompasses the use of variants, derivatives, analogs, homologs and fragments thereof.

[0240] In the context of the present invention, a variant of any given sequence is a sequence in which the residues (amino acid or nucleic acid residues) of that particular sequence have been modified in such a way that the polypeptide or polynucleotide in question substantially retains its function. Variant sequences can be obtained by addition, deletion, substitution, modification, replacement and / or mutation of at least one residue present in the naturally occurring protein.

[0241] The term "derivative" as used herein, in relation to a protein or polypeptide of the invention, includes any substitution, mutation, modification, exchange, deletion and / or addition of one (or more) amino acid residues from or to the sequence, provided that the resulting protein or polypeptide substantially retains at least one of its endogenous functions.

[0242] As used herein, the term "analog" with reference to a polypeptide or polynucleotide includes any mimetic, i.e., a chemical compound that retains at least one of the endogenous functions of the polypeptide or polynucleotide being mimicked.

[0243] Typically, amino acid substitutions may be made, for example from 1, 2 or 3 to 10 or 20 substitutions, provided that the modified sequence substantially retains the desired activity or potency. Amino acid substitutions may include the use of non-naturally occurring analogues.

[0244] Proteins for use in the present invention may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent protein. Deliberate amino acid substitutions can be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and / or amphipathic nature of the residues, so long as their endogenous function is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid, positively charged amino acids include lysine and arginine, and amino acids with uncharged polar head groups with similar hydrophilicity values ​​include asparagine, glutamine, serine, threonine and tyrosine.

[0245] Conservative substitutions can be made, for example, according to the following table. Amino acids in the same block in the second column and preferably in the same line in the third column can be substituted for each other: JPEG2024156706000015.jpg49131

[0246] As used herein, the term "homolog" refers to a substance that has a certain homology with a wild-type amino acid sequence and a wild-type nucleotide sequence. The term "homology" can be considered equivalent to "identity."

[0247] A homologous sequence may comprise an amino acid sequence which may be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% identical, preferably at least 95% or 97% or 99% identical to the subject sequence. Typically, said homologue comprises the same active site etc. as the subject amino acid sequence. Although homology may be considered in terms of similarity (i.e. amino acid residues having similar chemical properties / functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

[0248] A homologous sequence may comprise a nucleotide sequence which may be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% identical, preferably at least 95% or 97% or 99% identical to the subject sequence. Although homology can also be considered in terms of similarity, in the context of the present invention it is preferred to express homology in terms of sequence identity.

[0249] Preferably, references to sequences having a percent identity to any one of the SEQ ID NOs detailed herein refer to sequences having the stated percent identity over the entire length of the referenced SEQ ID NO.

[0250] Homology comparisons can be performed by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate the percent homology or percent identity between two or more sequences.

[0251] Percent homology may be calculated over contiguous sequences, i.e., one sequence is aligned with the other and each amino acid in one sequence is directly compared to the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively small number of residues.

[0252] While this is a very simple and consistent method, it does not take into account that, for example, in an otherwise identical pair of sequences, a single insertion or deletion in a nucleotide sequence may result in the next codon being excluded from the alignment, thus resulting in a large decrease in percent homology when performing a global alignment. As a result, most sequence comparison methods are designed to produce an optimal alignment that takes into account possible insertions and deletions without unduly penalizing the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to attempt to maximize local homology.

[0253] However, these more complex methods assign a "gap penalty" to each gap that occurs in the alignment, so that a sequence alignment with as few gaps as possible (reflecting a higher relatedness between the two compared sequences) achieves a higher score than a sequence alignment with many gaps, for the same number of identical amino acids. Typically, an "affine gap cost" is used, which imposes a relatively high cost for the presence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will naturally produce an optimized alignment that contains fewer gaps. Most alignment programs allow the gap penalty to be modified. However, it is preferred to use the default values ​​when using such software for sequence comparison. For example, when using the GCG Wisconsin Bestfit package, the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

[0254] Calculation of maximum percent homology therefore requires first generating an optimal alignment taking into account gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, USA; Devereux et al. (1984) Nucleic Acids Res. 12:387). Examples of other software capable of carrying out sequence comparisons include, but are not limited to, the BLAST package of comparison tools (see Ausubel et al. (1999) ibid - Ch. 18), FASTA (Atschul et al. (1990) J. Mol. Biol. 403-410) and the GENEWORKS integrated software package. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al. (1999) ibid, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. Another tool called BLAST 2 Sequences is also available for comparing protein and nucleotide sequences (see FEMS Microbiol. Lett. (1999) 174:247-50; FEMS Microbiol. Lett. (1999) 177:187-8).

[0255] Although the final percent homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pairwise comparison. Instead, a scaled similarity score matrix is ​​usually used, which assigns a score to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix (the default matrix for programs in the BLAST suite of software). GCG Wisconsin programs normally use the public default values, or a custom symbol comparison table if one has been supplied (see the user manual for further details). For some applications, it is preferred to use the public default values ​​for the GCG package, or a default matrix such as BLOSUM62 for other software.

[0256] Once the software has produced an optimal alignment, it is possible to calculate percent homology, preferably percent sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

[0257] "Fragments" of full-length Factor I or Factor H are also variants, and the term typically refers to selected regions of a polypeptide or polynucleotide that are functionally important, or for example, in an assay. Thus, a "fragment" refers to an amino acid sequence or nucleic acid sequence that is a portion of a full-length polypeptide or polynucleotide.

[0258] Such variants may be prepared using standard recombinant DNA techniques, such as site-directed mutagenesis. If an insertion is to be made, synthetic DNA may be made that encodes the insert, along with 5' and 3' flanking regions that correspond to the naturally occurring sequence on either side of the insertion site. The flanking regions contain convenient restriction sites that correspond to sites in the naturally occurring sequence, so that the sequence can be cleaved with an appropriate enzyme(s) and the synthetic DNA ligated to the cleavage. The DNA is then expressed according to the invention to produce the encoded protein. These methods are merely illustrative of the many standard techniques known in the art for manipulating DNA sequences, and other known techniques are similarly available.

[0259] Various preferred features and embodiments of the present invention are described herein by way of non-limiting examples.

[0260] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, biochemistry, molecular biology, microbiology and immunology which are within the capabilities of those skilled in the art. Such techniques are explained in the literature. See, e.g., Sambrook, J., Fritsch, EF, and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press; Ausubel, FM et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, Ch. 9, 13, and 16, John Wiley and Sons; Roe, B., Crabtree, J., and Kahn, A. (1996) DNA Isolation and Sequencing: Essential Techniques, John Wiley and Sons; Polak, JM, and McGee, J.O'D (1990) In Situ Hybridization: Principles and Practice, Oxford University Press; Gait, MJ (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; and Lilley, DM, and Dahlberg, JE (1992) Methods in Enzymology: DNA Structures Part I. A: Synthesis and Physical Analysis of DNA, Academic Press, each of which is incorporated herein by reference. EXAMPLES

[0261] Example 1 Cloning of human CFI cDNA and generation of CBA-CFI-WPRE expression cassette, construction of pAAV-CBA-CFI-WPRE-bGHpA, and packaging of AAV-CFI virus. The cDNA of the most common human CFI sequence variant was downloaded from Genbank under the accession number NM_000204.4. The cDNA has the sequence of SEQ ID NO:2 and was ordered from Integrated DNA Technologies as gBlocks® Gene Fragments. A second CFI construct was ordered as well, in which the cDNA sequence of the CFI gene was codon-optimized for expression in human cells. This codon-optimized sequence ("CFIco") has the sequence of SEQ ID NO:8 and was ordered from GeneWiz (CFIco in plasmid pUC57).

[0262] These cDNA sequences were inserted into a pAAV cis plasmid, designated pAM. pAM is a high copy number plasmid originally derived from pBR322, but containing stabilized AAV-2 left and right inverted terminal repeat sequences flanking the optimal expression cassette. For the AAV-CFI and AAV-CFIco vectors, a modified CBA / CAG promoter (chicken β-actin with CMV enhancer; referred to herein as "CBA") was used to drive the expression of CFI and CFIco, and a modified WPRE sequence and bGH polyA were provided 3' of the cDNA. These two plasmids were named pAAV2.CBA-hCFI-WPRE-bGH (pAAV-CFI) and pAAV2.CBA-hCFIco-WPRE-bGH (pAAV-CFIco).

[0263] Figure 2 shows an agarose gel of the restriction digests of CFI and CFIco. The 1752 bp band of CFI was excised and cloned into the pAAV-CBA-WPRE-bGHpA backbone.

[0264] Comparison of CFI expression levels of pAAV.CFI and pAAV.CFIco, cotransfection of ARPE-19 cell line with pAAV-CFI or pAAV.CFIco and pCMV.GFP, and immunoblotting of CFI. ARPE-19 (ATCC® CRL-2302™) is a spontaneous retinal pigment epithelial (RPE) cell line obtained in 1986 by Amy Aotaki-Keen from the normal eye of a 19-year-old male who died from head trauma in a car accident. These cells form stable adherent monolayers that exhibit morphological polarization when plated on laminin-coated Transwell-COL filters in medium with low serum concentrations. ARPE-19 cells were obtained from the American Type Culture Collection (ATCC). Cells were grown in DMEM / F12 (Thermo Fisher Scientific) supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 1% 200 mM L-glutamine (Sigma Aldrich), and 1% penicillin-streptomycin (Sigma Aldrich, 10,000 units penicillin, 10 mg streptomycin / mL).

[0265] Co-transfection of ARPE-19 was performed using Lipofectamine LTX (Life Technologies) according to the manufacturer's protocol. 0.5 μg of pAAV-CFI or pAAV.CFIco was co-transfected with 0.5 μg of pCMV.GFP (Plasmid Factory). Co-transfection of pAAV-CBA-WPRE-bGHpA (pAAV [without transgene cassette]) served as a negative control. 24 hours after transfection, cells were washed with PBS (phosphate buffered saline, pH 7.2, Gibco™) and cultured in serum-free growth medium for 72 hours. Supernatants were harvested, clarified by centrifugation, and stored at -80°C. ARPE-19 cells were detached with TrypLE Express (Gibco) and counted to ensure equal numbers of cells per well. Pellets were frozen at -20°C for 30 minutes. 1xRIPA lysis buffer (Merck Millipore) supplemented with cOmplete™ EDTA-free Protease Inhibitor Cocktail (Roche) was added to the pellet and cells were disrupted by sonication. Insoluble proteins were pelleted by centrifugation and the supernatant (=lysate) was stored at -80°C.

[0266] Immunoblotting for CFI was performed by loading 30 μL of undiluted supernatant in 4× Laemmli buffer (250 mM Tris-HCl (pH 6.8), 8% SDS, 40% glycerol, and 0.02% bromophenol blue) and separating proteins on a 10% precast polyacrylamide gel (Bio-Rad). Proteins were blotted onto a PVDF membrane (Bio-Rad) by semi-dry transfer, and the membrane was then blocked with blocking buffer (1×TBS pH 8 [Sigma], 0.05% Tween-20, and 5% powdered nonfat milk [Marvel]). CFI was detected with OX21 (Table 1) and anti-mouse IgG HRP-conjugated antibodies (Table 1) diluted in blocking buffer. Protein bands were visualized using Clarity Western ECL Substrate (Bio-Rad) and analyzed using the Odyssey® Fc Imaging System. Immunoblotting for GFP was performed by loading 5 μL of undiluted supernatant in 4x Laemmli buffer supplemented with 50 μL / mL β-mercaptoethanol. Immunoblots were performed as previously described. GFP was detected using an antibody against TurboGFP (Table 1) and an anti-rabbit IgG HRP-conjugated antibody (Table 1).

[0267] [Table 1]

[0268] Figure 3 shows immunoblotting for CFI (Figure 3A) and GFP (Figure 3B). 3A: CFI appeared as a 70 kDa band (non-reduced) and was expressed in equal proportions after transfection of ARPE-19 with pAAV.CFI or pAAV.CFIco. CFI was not expressed after transfection with pAAV. 10% normal human serum (NHS) was used as a positive control for CFI immunoblotting. 3B: Transfection efficiency was analyzed by cotransfection of ARPE-19 cells with pCMV.GFP. GFP appeared as a 30 kDa band and the immunoblot confirmed that the cells were transfected with similar efficiency.

[0269] Preparation of AAV.CFI and AAV.CFIco AAV2 virus was prepared by double transfection of HEK-293 (ATCC® CRL-1573™) or HEK-293T (ATCC® CRL-3216™) cell lines (both adherent) with pAAV.CFI or pAAV.CFIco and pDG (Plasmid Factory), which provides adenoviral helper and packaging sequences (Rep / Cap). HEK-293 and HEK-293T cells were grown in DMEM (Sigma) supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 1% 200 mM L-glutamine (Sigma Aldrich), and 1% penicillin-streptomycin (Sigma Aldrich, 10,000 units penicillin, 10 mg streptomycin / mL). Cells were harvested after 72 hours and lysed to purify viral particles. AAV particles were purified on an iodixanol gradient and collected from the 40% fraction. Virus was concentrated using Amicon Ultra-15 centrifugal filter units (Merck Millipore), aliquoted, and stored at -80°C. Viral purity was assessed by SDS PAGE, and titers were measured by qPCR.

[0270] In vitro expression analysis of AAV.CFI, AAV.CFIco and AAV.GFP, transduction of HEK-293 and ARPE-19 cell lines, and immunoblotting of tissue culture supernatants to analyze CFI expression 70% confluent HEK-293 ("293") and ARPE-19 cell lines were cultured at 1 × 10 in normal growth medium supplemented with 1% heat-inactivated fetal bovine serum alone. 4 Cells were transduced with AAV.CFI, AAV.CFIco, and AAV.GFP at a multiplicity of infection (MOI) of 100 ng / mL. After 7 days, supernatants were harvested and clarified by centrifugation. Supernatants were aliquoted and stored at -80°C.

[0271] Immunoblotting was performed as described previously, with 30 μL of supernatant mixed with 4× Laemmli buffer before loading onto a 10% precast polyacrylamide gel. CFI was detected with OX21 (Table 1) and anti-mouse IgG HRP-conjugated antibodies (Table 1) diluted in blocking buffer (supernatants were loaded under non-reducing conditions), or with antiserum against human CFI (Table 1) and anti-goat IgG (whole molecule)-peroxidase antibodies (Table 1) (supernatants were loaded under reducing conditions).

[0272] Figure 4 shows immunoblotting of CFI in the supernatants of virally transduced HEK-293 and ARPE-19 cell lines. 4A: Supernatants were loaded under non-reducing conditions and CFI was detected using a mouse monoclonal antibody against human CFI (OX21, Thermo Fisher Scientific) and a donkey anti-mouse IgG HRP-conjugated antibody (Abcam). CFI and CFIco were expressed in both cell lines. Transduction of cell lines with AAV.GFP served as a negative control, while 0.5 μg of plasma-purified human CFI (herein referred to as "CFIpl") (Comptech) served as a positive control. 4B: Supernatants were loaded under reducing conditions and CFI was detected using a goat antiserum against human CFI (Comptech) and a rabbit anti-goat IgG (whole molecule)-peroxidase antibody (Sigma). CFI appeared at 80 kDa (proenzyme), 50 kDa (processed; heavy chain) and 35 kDa (processed; light chain). AAV.GFP served as a negative control, while 0.5 μg of plasma purified human CFI (Comptech) and 10% normal human serum (referred to herein as "NHS") served as positive controls. CFI and CFIco were expressed in both cell lines.

[0273] Qualitative analysis of CFI expression, C3b cleavage assay to measure functional activity For qualitative analysis, CFI was immunoprecipitated using the Pierce Co-Immunoprecipitation (Co-IP) Kit (Thermo Fisher Scientific) according to the manufacturer's protocol. Thirty micrograms of affinity-purified monoclonal antibody against human CFI (Ox21, Thermo Fisher Scientific) was incubated with 25 μL of AminoLink Plus Coupling Resin for 2 hours at room temperature. Supernatants from HEK-293-transduced or ARPE-19-transduced cells were incubated with the prepared resin overnight at 4°C. The next day, the resin was washed several times using the provided IP Lysis / Wash Buffer. Bound CFI was eluted with the kit's elution buffer (0.1 M glycine, pH 2.7) and immediately neutralized with 1 M Tris, pH 9.5. Immunoprecipitation of CFI was assessed by measuring absorbance at 280 nm and by SDS PAGE analysis. CFI was either used directly in the C3b cleavage assay or aliquoted and stored at -80°C.

[0274] For the C3b cleavage assay, 1 mg of plasma-purified C3b was incubated with 0.5 μg of plasma-purified complement factor H (CFH) and plasma-purified complement factor I (CFIpl) (all plasma-purified proteins were obtained from Comptech), cell culture supernatants of AAV.CFI-transduced cells, or immunoprecipitated CFI / CFIco at 37°C for 1 h. The reaction was stopped by adding 4x Laemmli buffer containing β-mercapto-ethanol. Samples were diluted and loaded onto 10% precast polyacrylamide SDS PAGE gels (Bio-Rad). After transfer to a PVDF membrane (Bio-Rad) and blocking with blocking buffer (1x TBS pH 8 [Sigma] / 0.05% Tween-20 and 5% nonfat dry milk powder [Marvel]), C3b cleavage was detected using biotinylated Clone 9 (Table 1) and Extravidin-HRP conjugate (Table 1). This antibody reacts with an epitope on C3g and recognizes the α-chain of C3, the α'-chain of C3b, the C3α'1-chain of iC3b, and C3dg on reducing SDS PAGE. Therefore, it can be used to analyze the degradation of C3b by CFI. CFH serves as a cofactor for the degradation of C3b and, because the assay is performed at low ionic strength, CFH also serves as a cofactor for the second cleavage of iC3b to C3dg. The buffer used was the "Elution Buffer" of the Pierce Co-Immunoprecipitation (Co-IP) Kit (Thermo Fisher Scientific) neutralized with 1 M Tris, pH 9.5.

[0275] Figure 5 shows representative results of a C3b cleavage assay. Lane 1 shows C3b incubated with CFH alone. Lane 2 shows C3b incubated with CFH and CFIpl. C3b is degraded by CFIpl to iC3b and C3dg. Lane 3 shows C3b incubated with CFH and supernatant from HEK-293 transduced with AAV.CFI. Lanes 4-5 show C3b incubated with CFH and CFI immunoprecipitated (indicated as "IP CFI") from ARPE-19 cells transduced with AAV.CFI (lane 4) or AAV.CFIco (lane 5). Lanes 6-7 show C3b incubated with CFH and CFI immunoprecipitated from HEK-293 transduced with AAV.CFI (lane 6) or AAV.CFIco (lane 7). CFI secreted from transduced cell lines is functionally active and cleaves the α-chain of C3b to iC3b. Immunoprecipitation of CFI results in an increase in the amount of total CFI, reflected by the appearance of a C3dg band in addition to the α'1 fragment band of iC3b. This second cleavage only occurs at low ionic strength and at a low rate, so more CFI must be present.

[0276] In vitro analysis of CFI expression in transduced ARPE-19 cells grown on permeable transwell filters RPE cells are pigmented, non-dividing cells that exhibit morphological polarization when plated on laminin-coated Transwell-COL filters in medium with low serum concentrations. The Transwell filters (polyester membrane inserts, 0.4 μm pore diameter, 12 mm membrane diameter) serve to separate the culture well into two compartments: an apical (upper) portion, which corresponds to the retina-facing side of the RPE monolayer, and a basolateral (lower) portion, which corresponds to the choroid-facing side of the RPE monolayer. When placed under low serum medium conditions, ARPE-19 cells differentiate into hexagonal, less pigmented cells. This Transwell model allows the evaluation of expression in resting cells, reflecting the in vivo situation.

[0277] Transwells were coated with 8 μg / mL laminin (Sigma) and ARPE-19 cells were seeded in 10% FBS medium as a monolayer on the transwells. After 48 hours, the medium was changed to 1% FBS medium and the cells were seeded at an MOI of 10. 5 Cells were transduced with AAV.CFI, AAV.CFIco and AAV.GFP. After 7 days, supernatants were collected from both compartments and clarified by centrifugation. As the upper and lower compartments have different volumes, i.e. 500 μL medium in the upper compartment and 1500 μL medium in the lower compartment, the supernatants were analyzed normalized to the total volume: 30 μL of supernatant from the lower compartment was mixed with 4× Laemmli buffer and 10 μL of supernatant from the upper compartment was mixed with 4× Laemmli buffer. Samples were loaded on a 10% precast polyacrylamide gel. CFI was detected using OX21 (Table 1) and anti-mouse IgG HRP-conjugated antibodies (Table 1) diluted in blocking buffer. For nuclear staining, cells were washed twice with PBS (Gibco), fixed with 4% paraformaldehyde (Sigma) in PBS for 15 min, and permeabilized with 1% BSA (Thermo Fisher Scientific)-0.1% Triton X-100 (Sigma) in PBS for 45 min. Hoechst (Thermo Fisher Scientific) was incubated at 1:5000 in permeabilization buffer for 15 min and assessed for nuclear staining.

[0278] Figure 6 shows immunoblotting of secreted CFI from ARPE-19 cells cultured in transwells. The cells were not differentiated into hexagonal cells, but were cultured as a confluent monolayer of cells, and cell division was minimized by the addition of 1% serum medium. 6A: Supernatants from both compartments were loaded under non-reducing conditions, and Western blot analysis was performed using a mouse monoclonal against CFI (Ap = apical compartment and Bl = basolateral compartment). It is shown that CFI is expressed from a confluent monolayer of cells, and that secreted protein is detected in both compartments. 6B: Hoechst staining of nuclei was performed to confirm the presence of a monolayer of cells (staining was performed after harvesting the supernatant).

[0279] In vivo expression analysis of AAV.CFI and AAV.CFIco, subretinal injection in C57 / Black 6 mice, and analysis of CFI expression by immunoblotting, qPCR, and immunohistochemistry. subretinal injection Female C57BL / 6J mice (Charles River Laboratories), 8–10 weeks old, were used for all experiments. All animals used in this study were handled humanely in accordance with UK Home Office Regulations and under Project Licence 30 / 3363. Mice were maintained on a 12:12 h light / dark cycle.

[0280] Mice were anesthetized with a mixture of xylazine (10 mg / kg) / ketamine (80 mg / kg) in sterile saline; pupils were dilated with phenylephrine hydrochloride (2.5%) and tropicamide (1%). Proxymetacaine hydrochloride (0.5%) eye drops were used for additional local anesthesia. Prior to subretinal injection, anterior chamber paracentesis was performed using a sterile 33G needle (TSK Laboratory) and carbomer gel (Viscotears, Novartis Pharmaceuticals Ltd), and good visualization of the fundus was achieved by using a small round glass coverslip. The injection was performed through the posterior retina using a 10 μL NanoFil syringe and a 35G beveled NanoFil needle (World Precision Instruments Ltd). Anesthesia was reversed with atipamezole (2 mg / kg) in sterile saline.

[0281] Mice were administered two different doses (10 7 Genome copies [gc] / eye and 10 8 gc / eye) with two AAV constructs (AAV.CFI and AAV.CFIco). Three mice received a third dose of 10 9 gc / eye was injected with AAV.CFIco; these mice were used for calibration of immunoblots. Virus was diluted in 0.001% PF68 (Gibco) in PBS (Gibco) and sham injections were performed using the same diluent. Subretinal injections were performed in 12 eyes per condition.

[0282] Preparation of tissue samples for CFI immunoblotting Mice were sacrificed by cervical dislocation 4 weeks after injection. Eyes were removed and prepared as follows: An incision was made in the cornea using a dissecting microscope. Eyes were separated into cornea / iris (anterior), lens, and posterior eye cup. For whole eye cup samples, the posterior eye cup was placed in a sterile tube. For some eyes, the retina and RPE / choroid / sclera were separated by gently peeling the retina away from the RPE / choroid / sclera complex. Samples from three mice per condition were pooled (Figure 7A), while samples from two mice were pooled to compare with the non-injected contralateral eye, 10 9The AAV.CFIco-injected eye of gc / eye (Figure 7B) was excluded. All samples were immediately placed on dry ice to prevent proteolysis and kept at -80°C. For immunoblotting, samples were homogenized in 1x RIPA lysis buffer (Merck Millipore) supplemented with cOmplete™ EDTA-free Protease Inhibitor Cocktail (Roche), and cells were mechanically disrupted with a mortar and pestle and by sonication. Insoluble proteins were pelleted by centrifugation, and the supernatant was then aliquoted and stored at -80°C. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), and 40 μg of protein lysate was placed in 4x Laemmli buffer (250 mM Tris-HCl (pH 6.8), 8% SDS, 40% glycerol, and 0.02% bromophenol blue). Proteins were separated on 10% precast polyacrylamide gels (Bio-Rad). Proteins were blotted onto PVDF membranes (Bio-Rad) by semi-dry transfer, and the membranes were then blocked with blocking buffer (1xTBS pH 8 [Sigma], 0.05% Tween-20, and 5% powdered nonfat milk [Marvel]). CFI was detected using a) reduced: antiserum against human CFI (Table 1) and anti-goat IgG-HRP conjugated (Table 1), or b) non-reduced: OX21 (Table 1) and donkey anti-mouse IgG HRP conjugated antibody (Abcam) diluted in blocking buffer. For β-actin detection, the membranes were stained with the Restore Western Blot Strip. The cells were stripped using Blocking Buffer (Thermo Fisher Scientific) and redetected using anti-β-actin (Table 1) and anti-mouse IgG HRP-conjugated antibodies (Table 1) diluted in Blocking Buffer. Alternatively, mouse anti-β-actin antibody was used in combination with goat antiserum against CFI.

[0283] Figure 7 shows CFI protein expression of pooled samples analyzed by immunoblotting. CFI is expressed at detectable levels from both AAV.CFI and AAV.CFIco at all doses. β-actin was loaded as a loading control. 7A: 40 μg of protein lysate was loaded under reducing conditions and CFI was detected using a polyclonal goat antiserum against human CFI. CFI is detected as 80 kDa (proenzyme), 50 kDa (processed; heavy chain) and 35 kDa (processed; light chain). These bands are consistent with the expected size of CFI, confirming the presence of processing, i.e., heavy and light chains. 7B: 10 9 For lysate samples from gc / eye AAV.CFIco-injected or non-injected eyes, equal amounts of protein lysate were similarly loaded. CFI was detected using a mouse monoclonal against CFI (left, non-reduced gel) and a goat antiserum against CFI (right, reduced gel). In the non-reduced gel (left), CFI is detected as a 75 kDa band in injected animals and no band is detected in non-injected eyes. In the reduced gel (right), CFI appears as 80 kDa (proenzyme), 50 kDa (processed; heavy chain) and 35 kDa (processed; light chain).

[0284] Preparation of tissue samples for gene expression analysis Mice were sacrificed as described above, and either the posterior eyecup was kept intact or the retina and RPE were isolated as described above. Tissue samples were immediately placed into sterile tubes containing RNALater (Thermo Fisher Scientific). Samples were kept at 4°C until further processing. RNA was isolated using RNeasy Mini kit (Qiagen) and tissue was homogenized using a mortar and pestle in buffer RLT (supplied with the kit). The absence of genomic DNA was ensured by adding a complementary treatment with RNase-free DNase (Qiagen). 100 ng of RNA was reverse transcribed into cDNA using Superscript III First Strand Synthesis kit (Thermo Fisher Scientific). After reverse transcription, reactions were cleaned up using QIAquick PCR Purification Kit (Qiagen). qPCR was performed using the CFX Connect™ Real-Time PCR Detection System (Bio Rad) with one condition (sham, CFI 10 7 gc / eye, CFI 10 8 gc / eye, CFIco 10 7 gc / eye and CFIco 10 8 qPCR was performed on cDNA from one eye per well (gc / eye). 1.25 ng of cDNA was used per well as template for qPCR reactions with SYBR green master mix (iTaq Universal SYBR Green Supermix, Bio Rad). Each condition was performed in triplicate; Ct values ​​were obtained using the provided software. Relative expression of CFI to mock controls was determined using comparative ΔΔCt analysis using mouse β-actin as a housekeeping gene.

[0285] Figure 8 shows gene expression analysis by qPCR. As expected, no expression of human CFI or CFIco was observed in sham-injected mice. As only one eye per condition was analyzed, statistical analysis could not be performed. CFI was expressed from both AAV constructs, and expression apparently occurred predominantly in the RPE, although it was not observed in the 10 8 Injection of gc / eye results in increased CFI mRNA expression in retinal tissue. In eye cup samples, the amount of CFI mRNA relative to total eye cup mRNA is expected to be less than in RPE alone, because many regions of the eye do not show CFI expression; this is reflected in the results.

[0286] Preparation of retinal sections for immunohistochemistry Mice were sacrificed by cervical dislocation (4 weeks after injection). Eyes were removed and prepared as follows: a hole was made just behind the ora serrata and the globe was placed in 4% (w / v) paraformaldehyde in 0.12 M phosphate buffer, pH 7.2, at room temperature for 1 hour. We then removed the anterior segment and the lens and prepared the eye for sectioning or whole-mounting. Eye cups used for sectioning were cryopreserved in increasing concentrations of sucrose in 0.12 M phosphate buffer, pH 7.2 (10% for 1 hour at room temperature and 30% overnight at +4°C), embedded in OCT (Tissue-tek, Sakura Finetek USA inc, Ca, USA), molded and frozen at -80°C. Sections were cut at a thickness of 10 μm on a cryostat and mounted on glass slides (Super-Frost, Thermo Fisher Scientific, Waltham, MA, USA). The slides were air-dried at room temperature for 2 hours and then stored at −80° C. For eyecups used for whole mounts, the retina and RPE / choroid were separated by gently peeling the retina from the RPE and stored separately in PBS at +4° C.

[0287] immunostaining Sections were blocked and permeabilized by incubation in PBSGT solution (0.2% (w / v) gelatin, 0.25% (v / v) Triton X-100 in PBS) for 60 min at room temperature. Whole tissues were blocked and permeabilized by incubation in 0.2% (w / v) gelatin, 1.5% (v / v) Triton X-100 in PBS for 2 h at room temperature. Sections and whole tissues were then incubated overnight at room temperature with primary antibodies (see Table 1) diluted in PBSGT solution. After washing in PBST solution (0.1% (v / v) Triton X-100 in PBS), sections and whole tissues were incubated with secondary antibodies conjugated to Alexa Fluor594 (Life Technologies, Thermo Fisher Scientific, Waltham, Massachusetts, USA) at a dilution of 1:5000 and stained with DAPI in PBSGT solution for 1.5 h at room temperature. The slides were washed with PBST solution and then cover-slipped with mounting medium (Mowiol, Merck Millipore). [Table 2]

[0288] FIG. 9 shows the localization of fibronectin and hCFI in retinal sections of sham, AAV.CFI and AAV.CFIco injected eyes. Fibronectin is used as a co-marker to distinguish different retinal layers. For both AAV.CFI and AAV.CFIco injected eyes, hCFI is localized in several compartments, namely, slightly in the sclera (Scl), strongly in the RPE, outer segment (OS) and inner segment (IS) of photoreceptors, outer plexiform layer (OPL) and putatively in the ganglion cell layer (GCL) and nerve fiber layer (NFL). A weak signal in the GCL+NFL is seen for sham injected eyes, indicating that the antibody is not completely specific in these layers.

[0289] Figures 10-13 show higher magnifications of the various regions where hCFI is localized for retinal sections from sham and AAV.CFI-injected eyes. The same signals are observed for retinal sections from AAV.CFIco-injected eyes, but they are not shown.

[0290] Figure 10 shows higher magnification of the RPE region for retinal sections from sham and AAV.CFI-injected eyes. hCFI is localized throughout the RPE layer and to the microvilli of the RPE. The staining is vesicular, suggesting secretory pathway localization of hCFI.

[0291] Figure 11 shows higher magnification of the photoreceptor region for retinal sections from sham and AAV.CFI-injected eyes. hCFI was localized to the inner and outer segments of photoreceptors but was absent from the nuclear / endoplasmic reticulum region of the photoreceptors.

[0292] Figure 12 shows higher magnification of the outer plexiform layer for retinal sections from sham and AAV.CFI-injected eyes. hCFI was localized to the cell bodies, suggesting staining of horizontal cells. In the absence of horizontal cell markers, the following references show how expression in horizontal cells appears by immunohistochemistry: Poche et al. (2009), Development, 136:2141-51; Cuenca et al. (2010), Exp Eye Res., 91:273-85; Ho et al. (2012), PLoS One, 7:e29892.

[0293] Figure 13 shows higher magnification of the ganglion cell layer region for retinal sections from sham and AAV.CFI-injected eyes. The intensity of hCFI labeling in the nerve fiber layer in retinal sections from AAV.CFI-injected eyes appears higher relative to that in sham-injected eyes, but it is difficult to determine whether hCFI is localized to the nerve fiber layer.

[0294] Figure 14 shows the localization of fibronectin and hCFI in RPE whole preparations from sham, AAV.CFI and AAV.CFIco injected eyes. In both AAV.CFI and AAV.CFIco injected eyes, hCFI is localized to RPE cells. The staining is disrupted and appears to be localized to vesicles in the secretory pathway where hCFI is processed.

[0295] Example 2 In vivo functional assay of AAV.CFI or AAV.CFIco's ability to reduce light-induced retinal damage. Albino BALB / c mice are housed in the Animal Care Facility under a 12-hour light / 12-hour dark cycle with free access to food and water. Ambient light intensity at the animals' eye level is 85±18 lux. All experiments were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and approved by the UK Home Office.

[0296] As a model of geographic atrophy (Barbel Rohrer; Yao Guo; Kannan Kunchithapautham; Gary S. Gilkeson, Investigative Ophthalmology and Visual Science November 2007, Vol.48, 5282-5289), adult mice (approximately 1 year old) are moved to a light treatment room and dark-adapted overnight. Animals are housed in clear acrylic glass (Plexiglas; Rohm and Haas, Philadelphia, PA) cages, with two animals per cage, and with free access to food and water. Light damage is induced by exposing the animals to 1000 lux of white light provided by two 30-W compact fluorescent light bulbs (T30T12-CW-RS; General Electric, Piscataway, NJ) suspended approximately 40 cm above the cage. Light intensity is measured using a luminometer (Extech Instruments, Waltham, MA) to ensure that all animals are given equal luminance. This light dose reduces the number of rods to one row in albino mice within 2 to 3 weeks.

[0297] To investigate the role of complement factor I (CFI) in light-induced loss of outer retinal neurons, mice are injected with CFI-AAV.CFI (or AAV.CFIco), control GFP-AAV.GFP or sham via the subretinal route. Cohorts of 6–8 mice are typically used. Following 3–4 weeks of AAV exposure, light injury is initiated as detailed previously. After 2–3 weeks, electroretinography (ERG) is performed. Animals are anesthetized using xylazine and ketamine (20 and 80 mg / kg, respectively) and pupils are dilated with a drop of phenylephrine HCl (2.5%) and atropine sulfate (1%) before being placed in a heating block maintained at 37 °C in a light-tight Faraday cage. Light stimulation is delivered using an ERG device provided by Micron IV (Phoenix Labs). The light signal is controlled using a mechanical shutter, a manually operated neutral density, and a 500-nm bandpass filter. The light intensity per 10-ms flash delivered to this stimulation pathway was 3.0 × 10 5 From 3.0×10 11 Photons / mm 2 The ERG can be varied by 0.3 log units up to 1000 nm. Dark-adapted electroretinograms are recorded in response to single flash stimuli of increasing light intensity, averaging 3-5 responses. The a-wave peak amplitude is measured from baseline to the first negative going voltage, while the b-wave peak amplitude is measured from the a-wave trough to the positive b-wave peak. Following ERG, mouse eyes are obtained and processed using hematoxylin and eosin staining for histology and to quantify the thickness of the outer nuclear layer of the retina.

[0298] Reducing alternative complement pathway activity using CFI-AAV.CFI / AAV.CFIco exposure is predicted to preserve ERG function and reduce outer retinal neuronal loss.

[0299] In summary, adeno-associated virus is an effective vehicle to allow sustained expression of complement factor I, a regulator of the alternative complement pathway. Surprisingly, CFI delivered via AAV was shown to be expressed, correctly processed, and secreted in a functionally active form in both active and confluent human RPE cells. These data indicate that human RPE contains the proprotein convertase required to secrete CFI in a functional form. In animal translation experiments, subretinal delivery of CFI.AAV resulted in readily detectable expression of a functionally processed form of hCFI produced by mouse RPE cells. Immunostaining also suggested that despite the lack of mouse photoreceptors, intracellular expression of hCFI protein was present in the inner and nodal regions of the photoreceptors, suggesting that RPE-secreted hCFI may be diffuse and play its important regulatory role in the complement pathway in a broad area of ​​the choroid-retina. Given data linking complement dysregulation to age-related macular degeneration, this novel therapeutic approach may play a central role in the durable treatment of this blinding disease.

[0300] All publications mentioned in the above specification are incorporated herein by reference. Various modifications and variations of the described vectors, cells, compositions, uses and methods of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in terms of certain preferred embodiments, it will be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention will be apparent to those skilled in the art of biochemistry and biotechnology or related fields and are intended to be within the scope of the appended claims.

[0301] The present disclosure includes the following sequence information: SEQUENCE LISTING <110> SYNCONA IP HOLDCO LIMITED <120> Gene therapy <130> PA24-404 <140> JP 2024-112812 <141> 10-27-2016 <150> GB 1519086.1 <151> 10-28-2015 <160> 9 <170> PatentIn version 3.5 <210> 1 <211> 583 <212> PRT <213> Homo sapiens <400> 1 Met Lys Leu Leu His Val Phe Leu Leu Phe Leu Cys Phe His Leu Arg 1 5 10 15 Phe Cys Lys Val Thr Tyr Thr Ser Gln Glu Asp Leu Val Glu Lys Lys 20 25 30 Cys Leu Ala Lys Lys Tyr Thr His Leu Ser Cys Asp Lys Val Phe Cys 35 40 45 Gln Pro Trp Gln Arg Cys With Glu Gly Thr Cys Val Cys Leu Pro 50 55 60 Tyr Gln Cys Pro Lys Asn Gly Thr Ala Val Cys Ala Thr Asn Arg Arg 65 70 75 80 Ser Phe Pro Thr Tyr Cys Gln Gln Lys Ser Leu Glu Cys Leu His Pro 85 90 95 Gly Thr Lys Phe Leu Asn Asn Gly Thr Cys Thr Ala Glu Gly Lys Phe 100 105 110 Ser Val Ser Leu Lys His Gly Asn Thr Asp Ser Glu Gly Ile Val Glu 115 120 125 Val Lys Leu Val Asp Gln Asp Lys Thr Met Phe Ile Cys Lys Ser Ser 130 135 140 Trp Ser Met Arg Glu Ala Asn Val Ala Cys Leu Asp Leu Gly Phe Gln 145 150 155 160 Gln Gly Ala Asp Thr Gln Arg Arg Phe Lys Leu Ser Asp Leu Ser Ile 165 170 175 Asn Ser Thr Glu Cys Leu His Val His Cys Arg Gly Leu Glu Thr Ser 180 185 190 Leu Ala Glu Cys Thr Phe Thr Lys Arg Arg Thr Met Gly Tyr Gln Asp 195 200 205 Phe Ala Asp Val Val Cys Tyr Thr Gln Lys Ala Asp Ser Pro Met Asp 210 215 220 Asp Phe Phe Gln Cys Val Asn Gly Lys Tyr Ile Ser Gln Met Lys Ala 225 230 235 240 Cys Asp Gly Ile Asn Asp Cys Gly Asp Gln Ser Asp Glu Leu Cys Cys 245 250 255 Lys Ala Cys Gln Gly Lys Gly Phe His Cys Lys Ser Gly Val Cys Ile 260 265 270 Pro Ser Gln Tyr Gln Cys Asn Gly Glu Val Asp Cys Ile Thr Gly Glu 275 280 285 Asp Glu Val Gly Cys Ala Gly Phe Ala Ser Val Thr Gln Glu Glu Thr 290 295 300 Glu Ile Leu Thr Ala Asp Met Asp Ala Glu Arg Arg Arg Ile Lys Ser 305 310 315 320 Leu Leu Pro Lys Leu Ser Cys Gly Val Lys Asn Arg Met His Ile Arg 325 330 335 Arg Lys Arg Ile Val Gly Gly Lys Arg Ala Gln Leu Gly Asp Leu Pro 340 345 350 Trp Gln Val Ala Ile Lys Asp Ala Ser Gly Ile Thr Cys Gly Gly Ile 355 360 365 Tyr Ile Gly Gly Cys Trp Ile Leu Thr Ala Ala His Cys Leu Arg Ala 370 375 380 Ser Lys Thr His Arg Tyr Gln Ile Trp Thr Thr Val Val Asp Trp Ile 385 390 395 400 His Pro Asp Leu Lys Arg Ile Val Ile Glu Tyr Val Asp Arg Ile Ile 405 410 415 Phe His Glu Asn Tyr Asn Ala Gly Thr Tyr Gln Asn Asp Ile Ala Leu 420 425 430 Ile Glu Met Lys Lys Asp Gly Asn Lys Lys Asp Cys Glu Leu Pro Arg 435 440 445 Ser Ile Pro Ala Cys Val Pro Trp Ser Pro Tyr Leu Phe Gln Pro Asn 450 455 460 Asp Thr Cys Ile Val Ser Gly Trp Gly Arg Glu Lys Asp Asn Glu Arg 465 470 475 480 Val Phe Ser Leu Gln Trp Gly Glu Val Lys Leu Ile Ser Asn Cys Ser 485 490 495 Lys Phe Tyr Gly Asn Arg Phe Tyr Glu Lys Glu Met Glu Cys Ala Gly 500 505 510 Thr Tyr Asp Gly Ser Ile Asp Ala Cys Lys Gly Asp Ser Gly Gly Pro 515 520 525 Leu Val Cys Met Asp Ala Asn Asn Val Thr Tyr Val Trp Gly Val Val 530 535 540 Ser Trp Gly Glu Asn Cys Gly Lys Pro Glu Phe Pro Gly Val Tyr Thr 545 550 555 560 Lys Val Ala Asn Tyr Phe Asp Trp Ile Ser Tyr His Val Gly Arg Pro 565,570,575 Where To Be Gln Tyr Asn Val 580 <210> 2 <211> 1752 <212> DNA <213> Homo sapiens <400> 2 atgaagcttc ttcatgtttt cctgttattt ctgtgcttcc acttaaggtt ttgcaggtc 60 acttacat ctcagagga tctggtggag aaaaagtgct tagcaaaaaa atactcac 120 ctctcctgcg ataaagtctt ctgccagcca tggcagagat gcattgaggg cacctgtgtt 180 tgtaaactac cgtatcagtg cccaaagaat ggcactgcag tgtgtgcaac taacaggaga 240 agcttcccaa catactgtca aaagagt ttggaatgtc ttcatccagg gawaagtttt 300 ttaaataacg gaacatgcac agccgaagga aagtttagtg ttccttgaa gcatggaat 360 acagattcag agggaatagt tgaagtaaaa cttgtggacc aagatagac atgttcata 420 tgcaaagca gctggagcat gagggaagcc aacgtggcct gccttgacct tggttttcaa 480 caaggtgctg atactcaaag aaggtttaag ttgtctgatc tctctataaa ttccactgaa 540 tgcttacatg tgcattgccg aggattagag accagtttgg ctgaatgtac ttttactaag 600 agaagaacta tgggttacca ggatttcgct gatgtggtttt gttatacaca gaaagcagat 660 tctccaatgg atgacttctt tcagtgtgtg aatgggaaat acatttctca gatgaaagcc 720 tgtgatggta tcaatgattg tggagaccaa agtgatgaac tgtgttgtaa agcatgccaa 780 ggcaaaggct tccattgcaa atcgggtgtt tgcattccaa gccagtatca atgcaatggt 840 gaggtggact gcattacagg ggaagatgaa gttggctgtg caggctttgc atctgtggct 900 caagaagaaa cagaaatttt gactgctgac atggatgcag aaagaagacg gataaaatca 960 ttattaccta aactatcttg tggagttaaa aacagaatgc acattcgaag gaaacgaatt 1020 gtgggaggaa agcgagcaca actgggagac ctcccatggc aggtggcaat taaggatgcc 1080 agtggaatca cctgtggggg aatttatatt ggtggctgtt ggattctgac tgctgcacat 1140 tgtctcagag ccagtaaaac tcatcgttac caaatatgga caacagtagt agactggata 1200 caccccgacc ttaaacgtat agtaattgaa tacgtggata gaattatttt ccatgaaaac 1260 tacaatgcag gcacttacca aaatgacatc gctttgattg aaatgaaaaa agacggaaac 1320 aaaaaagatt gtgagctgcc tcgttccatc cctgcctgtg tcccctggtc tccttaccta 1380 ttccaaccta atgatacatg catcgtttct ggctggggac gagaaaaaga taacgaaaga 1440 gtcttttcac ttcagtgggg tgaagttaaa ctaataagca actgctctaa gttttacgga 1500 aatcgtttct atgaaaaaga aatggaatgt gcaggtacat atgatggttc catcgatgcc 1560 tgtaaagggg actctggagg ccccttagtc tgtatggatg ccaacaatgt gacttatgtc 1620 tggggtgttg tgagttgggg ggaaaactgt ggaaaaccag agttcccagg tgtttacacc 1680 aaagtggcca attattttga ctggattagc taccatgtag gaaggccttt tatttctcag 1740 tacaatgtat aa 1752 <210> 3 <211> 1231 <212> PRT <213> Homo sapiens <400> 3 Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys 1 5 10 15 Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile 20 25 30 Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala 35 40 45 Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met 50 55 60 Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys 65 70 75 80 Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe 85 90 95 Thr Leu Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr 100 105 110 Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu 115 120 125 Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val 130 135 140 Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser 145 150 155 160 Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe 165 170 175 Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys 180 185 190 Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile 195 200 205 Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys 210 215 220 Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly 225 230 235 240 Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp 245 250 255 Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile 260 265 270 Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp 275 280 285 Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly 290 295 300 Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys 305 310 315 320 Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr 325 330 335 His Glu Asn Met Arg Arg Pro Tyr Phe Pro Val Ala Val Gly Lys Tyr 340 345 350 Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr 355 360 365 Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro 370 375 380 Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln 385 390 395 400 Asn Tyr Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys 405 410 415 His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met 420 425 430 Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Lys Thr Cys 435 440 445 Ser Lys Ser Ser Ile Asp Ile Glu Asn Gly Phe Ile Ser Glu Ser Gln 450 455 460 Tyr Thr Tyr Ala Leu Lys Glu Lys Ala Lys Tyr Gln Cys Lys Leu Gly 465 470 475 480 Tyr Val Thr Ala Asp Gly Glu Thr Ser Gly Ser Ile Thr Cys Gly Lys 485 490 495 Asp Gly Trp Ser Ala Gln Pro Thr Cys Ile Lys Ser Cys Asp Ile Pro 500 505 510 Val Phe Met Asn Ala Arg Thr Lys Asn Asp Phe Thr Trp Phe Lys Leu 515 520 525 Asn Asp Thr Leu Asp Tyr Glu Cys His Asp Gly Tyr Glu Ser Asn Thr 530 535 540 Gly Ser Thr Thr Gly Ser Ile Val Cys Gly Tyr Asn Gly Trp Ser Asp 545 550 555 560 Leu Pro Ile Cys Tyr Glu Arg Glu Cys Glu Leu Pro Lys Ile Asp Val 565 570 575 His Leu Val Pro Asp Arg Lys Lys Asp Gln Tyr Lys Val Gly Glu Val 580 585 590 Leu Lys Phe Ser Cys Lys Pro Gly Phe Thr Ile Val Gly Pro Asn Ser 595 600 605 Val Gln Cys Tyr His Phe Gly Leu Ser Pro Asp Leu Pro Ile Cys Lys 610 615 620 Glu Gln Val Gln Ser Cys Gly Pro Pro Pro Glu Leu Leu Asn Gly Asn 625 630 635 640 Val Lys Glu Lys Thr Lys Glu Glu Tyr Gly His Ser Glu Val Val Glu 645 650 655 Tyr Tyr Cys Asn Pro Arg Phe Leu Met Lys Gly Pro Asn Lys Ile Gln 660 665 670 Cys Val Asp Gly Glu Trp Thr Thr Leu Pro Val Cys Ile Val Glu Glu 675 680 685 Ser Thr Cys Gly Asp Ile Pro Glu Leu Glu His Gly Trp Ala Gln Leu 690 695 700 Ser Ser Pro Pro Tyr Tyr Tyr Gly Asp Ser Val Glu Phe Asn Cys Ser 705 710 715 720 Glu Ser Phe Thr Met Ile Gly His Arg Ser Ile Thr Cys Ile His Gly 725 730 735 Val Trp Thr Gln Leu Pro Gln Cys Val Ala Ile Asp Lys Leu Lys Lys 740 745 750 Cys Lys Ser Ser Asn Leu Ile Ile Leu Glu Glu His Leu Lys Asn Lys 755 760 765 Lys Glu Phe Asp His Asn Ser Asn Ile Arg Tyr Arg Cys Arg Gly Lys 770 775 780 Glu Gly Trp Ile His Thr Val Cys Ile Asn Gly Arg Trp Asp Pro Glu 785 790 795 800 Val Asn Cys Ser Met Ala Gln Ile Gln Leu Cys Pro Pro Pro Pro Gln 805 810 815 Ile Pro Asn Ser His Asn Met Thr Thr Thr Leu Asn Tyr Arg Asp Gly 820 825 830 Glu Lys Val Ser Val Leu Cys Gln Glu Asn Tyr Leu Ile Gln Glu Gly 835 840 845 Glu Glu Ile Thr Cys Lys Asp Gly Arg Trp Gln Ser Ile Pro Leu Cys 850 855 860 Val Glu Lys Ile Pro Cys Ser Gln Pro Pro Gln Ile Glu His Gly Thr 865 870 875 880 Ile Asn Ser Ser Arg Ser Ser Gln Glu Ser Tyr Ala His Gly Thr Lys 885 890 895 Leu Ser Tyr Thr Cys Glu Gly Gly Phe Arg Ile Ser Glu Glu Asn Glu 900 905 910 Thr Thr Cys Tyr Met Gly Lys Trp Ser Ser Pro Pro Gln Cys Glu Gly 915 920 925 Leu Pro Cys Lys Ser Pro Pro Glu Ile Ser His Gly Val Val Ala His 930 935 940 Met Ser Asp Ser Tyr Gln Tyr Gly Glu Glu Val Thr Tyr Lys Cys Phe 945 950 955 960 Glu Gly Phe Gly Ile Asp Gly Pro Ala Ile Ala Lys Cys Leu Gly Glu 965 970 975 Lys Trp Ser His Pro Pro Ser Cys Ile Lys Thr Asp Cys Leu Ser Leu 980 985 990 Pro Ser Phe Glu Asn Ala Ile Pro Met Gly Glu Lys Lys Asp Val Tyr 995 1000 1005 Lys Ala Gly Glu Gln Val Thr Tyr Thr Cys Ala Thr Tyr Tyr Lys 1010 1015 1020 Met Asp Gly Ala Ser Asn Val Thr Cys Ile Asn Ser Arg Trp Thr 1025 1030 1035 Gly Arg Pro Thr Cys Arg Asp Thr Ser Cys Val Asn Pro Pro Thr 1040 1045 1050 Val Gln Asn Ala Tyr Ile Val Ser Arg Gln Met Ser Lys Tyr Pro 1055 1060 1065 Ser Gly Glu Arg Val Arg Tyr Gln Cys Arg Ser Pro Tyr Glu Met 1070 1075 1080 Phe Gly Asp Glu Glu Val Met Cys Leu Asn Gly Asn Trp Thr Glu 1085 1090 1095 Pro Pro Gln Cys Lys Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro 1100 1105 1110 Pro Ile Asp Asn Gly Asp Ile Thr Ser Phe Pro Leu Ser Val Tyr 1115 1120 1125 Ala Pro Ala Ser Ser Val Glu Tyr Gln Cys Gln Asn Leu Tyr Gln 1130 1135 1140 Leu Glu Gly Asn Lys Arg Ile Thr Cys Arg Asn Gly Gln Trp Ser 1145 1150 1155 Glu Pro Pro Lys Cys Leu His Pro Cys Val Ile Ser Arg Glu Ile 1160 1165 1170 Met Glu Asn Tyr Asn Ile Ala Leu Arg Trp Thr Ala Lys Gln Lys 1175 1180 1185 Leu Tyr Ser Arg Thr Gly Glu Ser Val Glu Phe Val Cys Lys Arg 1190 1195 1200 Gly Tyr Arg Leu Ser Ser Arg Ser His Thr Leu Arg Thr Thr Cys 1205 1210 1215 Trp Asp Gly Lys Leu Glu Tyr Pro Thr Cys Ala Lys Arg 1220 1225 1230 <210> 4 <211> 3696 <212> DNA <213> Homo sapiens <400> 4 atgagacttc tagcaaagat tatttgcctt atgttatggg ctatttgtgt agcagaagat 60 tgcaatgaac ttcctccaag aagaaataca gaaattctga caggttcctg gtctgaccaa 120 acatatccag aaggcaccca ggctatctat aaatgccgcc ctggatatag atctcttgga 180 aatgtaataa tggtatgcag gaagggagaa tgggttgctc ttaatccatt aaggaaatgt 240 cagaaaaggc cctgtggaca tcctggagat actccttttg gtacttttac ccttacagga 300 ggaaatgtgt ttgaatatgg tgtaaaagct gtgtatacat gtaatgaggg gtatcaattg 360 <h2 style=";text-align:left;direction:ltr">ctaggtgaga ttaattaccg tgaatgtgac acagatggat ggaccaatga tattcctata 420<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> tgtgaagttg tgaagtgttt accagtgaca gcaccagaga atggaaaaat tgtcagtagt 480<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gcaatggaac cagatcggga ataccatttt ggacaagcag tacggtttgt atgtaactca 540<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ggctacaaga ttgaaggaga tgaagaaatg cattgttcag acgatggttt ttggagtaaa 600<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gagaaaccaa agtgtgtgga aatttcatgc aaatccccag atgttataaa tggatctcct 660<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> atatctcaga agattattta taaggagaat gaacgatttc aatataaatg taacatgggt 720<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> tatgaataca gtgaaagagg agatgctgta tgcactgaat ctggatggcg tccgttgcct 780<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> tcatgtgaag aaaaatcatg tgataatcct tatattccaa atggtgacta ctcaccttta 840<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> aggattaaac acagaactgg agatgaaatc acgtaccagt gtagaaatgg tttttatcct 900<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gcaacccggg gaaataacagc aaaatgcaca agtactggct ggatacctgc tccgagatgt 960<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> accttgaaac cttgtgatta tccagacatt aaacatggag gtctatatca tgagaatatg cgtagaccat actttccagt agctgtagga aaatattact cctattactg tgatgaacat tttgagactc cgtcaggaag ttactgggat cacattcatt gcacacaaga tggatggtcg ccagcagtac catgcctcag aaaatgttat tttccttatt tggaaatgg father aatcatggaa gaaagtttgt acagggtaaa tctatagacg ttgcctgcca tcctggctac gctcttccaa aagcgcagac cacagttaca tgtatggaga atggctggtc tcctactccc agatgcatcc gtgtcaaaac atgttccaaa tcaagtatag attack tgggtttatt tctgaatctc agtatacata tgccttaaaa gaaaaagcga aatatcaatg caaactagga 1500. 1500. 1500. 1500. 1500. 1500. 1500. 1500. 1500. 1500. 1500 gctcaaccca cgtgcattaa atcttgtgat atcccagtat ttatgaatgc cagaactaaa aatgacttca catggtttaa gctgaatgac acattggact atgaatgcca tgatggttat 1620 gaaagcaata ctggaagcac cactggttcc atagtgtgtg gttacaatgg ttggtctgat 1680 ttacccatat gttatgaaag agaatgcgaa cttcctaaaa tagatgtaca cttagttcct 1740 gatcgcaaga aagaccagta taaagttgga gaggtgttga aattctcctg caaaccagga 1800 tttacaatag ttggacctaa ttccgttcag tgctaccact ttggattgtc tcctgacctc 1860 ccaatatgta aagagcaagt acaatcatgt ggtccacctc ctgaactcct caatgggaat 1920 gttaaggaaa aaacgaaaga agaatatgga cacagtgaag tggtggaata ttattgcaat 1980 cctagatttc taatgaaggg acctaataaa attcaatgtg ttgatggaga gtggacaact 2040 ttaccagtgt gtattgtgga ggagagtacc tgtggagata tacctgaact tgaacatggc 2100 tgggcccagc tttcttcccc tccttattac tatggagatt cagtggaatt caattgctca 2160 gatcattta caatgatttgg acacagatca attacgtta ttcatggagt atggaccca 2220 cttccccagt gtgtggcaat agataaactt aagagtgca atcatcaa tttatta 2280 cttgaggaac atttaaaaaa ttcgatcata attctacat aaggtacaga 2340 tgtagaggaa aagaaggatg gatacacaca gtctgcataa atggagatg ggatccagaa 2400 gtgaactgct caatggcaca atacaatta tgcccacctc cacctcagat tcccattct 2460 spider spider gattatcgg gatggagaa agtatctctgt tctttgccaa 2520 gaaaattatc taattcagga aggagaa attackacatgca aagatggaag atggcagtca 2580 ataccactct gtgttgaaa aattccactgt tcacaccac ctcagataga acacggaacc 2640 atttaatcat ccaggtcttc acagaaagt tatgcacatg ggactaatt gagttatact 2700 tgtgagggtg gtttcaggat atctgaagaa atgaaaca catgctacat gggaaaatgg 2760 agttctccac ctcagtgtga aggccttcct tgtaaatctc cacctgagat ttctcatggt 2820 gttgtagctc acatgtcaga cagttatcag tatggagaag aagttacgta caaatgtttt 2880 gaaggttttg gaattgatgg gcctgcaatt gcaaaatgct taggagaaaa atggtctcac 2940 cctccatcat gcataaaaac agattgtctc agtttaccta gctttgaaaa tgccataccc 3000 atgggagaga agaaggatgt gtataaggcg ggtgagcaag tgacttacac ttgtgcaaca 3060 tattacaaaa tggatggagc cattaatgta acatgcatta atagcagatg gacaggaagg 3120 ccaacatgca gagacacctc ctgtgtgaat ccgcccacag tacaaaatgc ttatatagtg 3180 tcgagacaga tgagtaaata tccatctggt gagagagtac gttatcaatg taggagccct 3240 3300 caatgcaaag attctacagg aaaatgtggg ccccctccac ctattgacaa tggggacatt 3360 acttcattcc cgttgtcagt atgctcca gcttcatcag ttgagtacca atgccagaac 3420 ttgtatcaac ttgaggtaa caagcgaata acatgtagaa atggacaatg gtcagaacca 3480 ccaaaatgct tacatccgtg tgtatatatcc cgagaaatta tggaaaatta taacatagca 3540 ttaggtgga cagccaaca gaagctttat tcgagacag gtgaatcagt tgaatttgtg 3600 tgtaaacggg gatatcgtct ttcatcacgt tctcacacat tgcgaacac atgttgggat gggaaactgg agtatccaac ttgtgcaaaa agatag 3696 <210> 5 <211> 934 <212> DNA <213> Artificial Sequence <220> <223> example promoter sequence <400> 5 attgacgtca ataatgacgt atgttcccat agtaacgcca atagggactt tccattgacg 60 tcaatgggtg gagtatttac ggtaaactgc ccacttggca gtacatcaag tgtatcat 120 gccaagtacg ccccctattg acgtcaatga cggtaaatgg cccgcctggc attatgccca 180 gtacatgacc ttatgggact ttcctacttg gcagtacatc tacgtattag tcatcgctat 240 taccatggtc gaggtgagcc ccacgttctg cttcactctc cccatctccc ccccctcccc 300 acccccaatt ttgtatttat ttatttttta attattttgt gcagcgatgg gggcgggggg 360 gggggggggg cgcgcgccag gcggggcggg gcggggcgag gggcggggcg gggcgaggcg 420 gagaggtgcg gcggcagcca atcagagcgg cgcgctccga aagtttcctt ttatggcgag 480 gcggcggcgg cggcggccct ataaaaagcg aagcgcgcgg cgggcgggag tcgctgcgcg 540 ctgccttcgc cccgtgcccc gctccgccgc cgcctcgcgc cgcccgcccc ggctctgact 600 gaccgcgtta ctcccacagg tgagcgggcg ggacggccct tctcctccgg gctgtaatta 660 gcgcttggtt taatgacggc ttgtttcttt tctgtggctg cgtgaaagcc ttgaggggct 720 ccgggagggc cctttgtgcg gggggagcgg ctcggggctg tccgcggggg gacggctgcc 780 ttcggggggg acggggcagg gcggggttcg gcttctggcg tgtgaccggc ggctctagag 840 cctctgctaa ccatgttcat gccttcttct ttttcctaca gctcctgggc aacgtgctgg 900 ttattgtgct gtctcatcat tttggcaaag aatt 934 <210> 6 <211> 270 <212> DNA <213> Artificial Sequence <220> <223> bovine growth hormone poly-A signal <400> 6 tcgctgatca gcctcgactg tgccttctag ttgccagcca tctgttgttt gcccctcccc 60 cgtgccttcc ttgaccctgg aaggtgccac tcccactgtc ctttcctaat aaaatgagga 120 aattgcatcg cattgtctga gtaggtgtca ttctattctg gggggtgggg tggggcagga 180 cagcaagggg gaggattggg aagacaatag caggcatgct ggggatgcgg tgggctctat 240 ggcttctgag gcggaaagaa ccagctgggg 270 <210> 7 <211> 588 <212> DNA <213> Woodchuck hepatitis virus <400> 7 atcaacctct ggattacaaa atttgtgaaa gattgactgg tattcttaac tatgttgctc 60 cttttacgct atgtggatac gctgctttaa tgcctttgta tcatgctatt gcttcccgta 120 tggctttcat tttctcctcc ttgtataaat cctggttgct gtctctttat gaggagttgt 180 ggcccgttgt caggcaacgt ggcgtggtgt gcactgtgtt tgctgacgca acccccactg 240 gttggggcat tgccaccacc tgtcagctcc tttccgggac tttcgctttc cccctcccta 300 ttgccacggc ggaactcatc gccgcctgcc ttgcccgctg ctggacaggg gctcggctgt 360 tgggcactga caattccgtg gtgttgtcgg ggaaatcatc gtcctttcct tggctgctcg 420 cctgtgttgc cacctggatt ctgcgcggga cgtccttctg ctacgtccct tcggccctca 480 atccagcgga ccttccttcc cgcggcctgc tgccggctct gcggcctctt ccgcgtcttc 540 gccttcgccc tcagacgagt cggatctccc tttgggccgc ctccccgc 588 <210> 8 <211> 1752 <212> DNA <213> Artificial Sequence <220> <223> nucleotide sequence encoding Factor I <400> 8 atgaagctgc tgcatgtctt tctgctgttt ctgtgcttcc atctgcggtt ctgtaaagtg 60 acctatacta gccaggagga tctggtggag aagaagtgtc tggccaagaa gtacacacac 120 ctgagctgcg acaaggtgtt ctgtcagcct tggcagcggt gcatcgaggg cacctgcgtg 180 tgcaagctgc cttaccagtg cccaaagaac ggcaccgccg tgtgcgccac aaatcggaga 240 tcttttccaa catattgcca gcagaagagc ctggagtgtc tgcaccccgg caccaagttc 300 ctgaacaatg gcacctgcac agccgagggc aagttttctg tgagcctgaa gcacggcaac 360 acagatagcg agggcatcgt ggaggtgaag ctggtggacc aggataagac catgttcatc 420 tgtaagagct cctggtccat gagggaggca aacgtggcat gcctggatct gggattccag 480 cagggagcag acacacagag gcgctttaag ctgtccgacc tgtctatcaa tagcaccgag 540 tgcctgcacg tgcactgtag gggcctggag acatccctgg cagagtgcac cttcacaaag 600 cggagaacca tgggctacca ggactttgcc gacgtggtgt gctataccca gaaggccgat 660 agccccatgg acgatttctt tcagtgcgtg aacggcaagt atatctccca gatgaaggcc 720 tgcgacggca tcaatgactg tggcgatcag tctgacgagc tgtgctgtaa ggcctgtcag 780 ggcaagggct tccactgcaa gagcggcgtg tgcatccctt cccagtacca gtgcaacggc 840 gaggtggatt gtatcacagg agaggacgaa gtgggatgcg caggatttgc atctgtggca 900 caggaggaga cagagatcct gacagccgac atggatgccg agaggcgccg gatcaagtct 960 ctgctgccta agctgagctg tggcgtgaag aatcggatgc acatcagaag gaagcgcatc 1020 gtgggaggca agagggcaca gctgggcgat ctgccatggc aggtggccat caaggacgcc 1080 tctggcatca cctgcggcgg catctacatc ggaggatgtt ggatcctgac cgcagcacac 1140 tgcctgagag caagcaagac acacaggtat cagatctgga ccacagtggt ggattggatc 1200 cacccagacc tgaagagaat cgtgatcgag tacgtggata ggatcatctt tcacgagaac 1260 tacaatgccg gcacatatca gaacgacatc gcctgatcg agatgaagaa ggatggcaat 1320 aagaaggact gtgagctgcc cagatccatc cctgcatgcg tgccatggag cccctatctg 1380 ttccagccca acgatacctg catcgtgtcc ggatggggaa gggagaagga caatgagcgg 1440 gtgttttctc tgcagtgggg cgaggtgaag ctgatctcca actgttctaa gttctacggc 1500 aataggtttt atgagaagga gatggagtgc gccggcacct acgatggcag catcgacgcc 1560 tgtaagggcg attccggagg accactggtg tgcatggacg caacaatgt gatacgtg 1620 tggggagtgg tgtcctgggg agagactgc ggcaagccag agttccccgg cgtatatacc 1680 aaggtggcca attattttga ttggattcc taccacgtcg gcaggccctt tattcccag 1740 father gtct aa 1752 <210> 9 <211> 583 <212> PRT <213> Homo sapiens <400> 9 Met Lys Leu Leu His Val Phe Leu Leu Phe Leu Cys Phe His Leu Arg 1 5 10 15 Phe Cys Lys Val Thr Tyr Thr Ser Gln Glu Asp Leu Val Glu Lys Lys 20 25 30 Cys Leu Ala Lys Lys Tyr Thr His Leu Ser Cys Asp Lys Val Phe Cys 35 40 45 Gln Pro Trp Gln Arg Cys With Glu Gly Thr Cys Val Cys Leu Pro 50 55 60 Tyr Gln Cys Pro Lys Asn Gly Thr Ala Val Cys Ala Thr Asn Arg Arg 65 70 75 80 Ser Phe Pro Thr Tyr Cys Gln Gln Lys Ser Leu Glu Cys Leu His Pro 85 90 95 Gly Thr Lys Phe Leu Asn Asn Gly Thr Cys Thr Ala Glu Gly Lys Phe 100 105 110 Ser Val Ser Leu Lys His Gly Asn Thr Asp Ser Glu Gly Ile Val Glu 115 120 125 Val Lys Leu Val Asp Gln Asp Lys Thr Met Phe Ile Cys Lys Ser Ser 130 135 140 Trp Ser Met Arg Glu Ala Asn Val Ala Cys Leu Asp Leu Gly Phe Gln 145 150 155 160 Gln Gly Ala Asp Thr Gln Arg Arg Phe Lys Leu Ser Asp Leu Ser Ile 165 170 175 Asn Ser Thr Glu Cys Leu His Val His Cys Arg Gly Leu Glu Thr Ser 180 185 190 Leu Ala Glu Cys Thr Phe Thr Lys Arg Arg Thr Met Gly Tyr Gln Asp 195 200 205 Phe Ala Asp Val Val Cys Tyr Thr Gln Lys Ala Asp Ser Pro Met Asp 210 215 220 Asp Phe Phe Gln Cys Val Asn Gly Lys Tyr Ile Ser Gln Met Lys Ala 225 230 235 240 Cys Asp Gly Ile Asn Asp Cys Gly Asp Gln Ser Asp Glu Leu Cys Cys 245 250 255 Lys Ala Cys Gln Gly Lys Gly Phe His Cys Lys Ser Gly Val Cys Ile 260 265 270 Pro Ser Gln Tyr Gln Cys Asn Gly Glu Val Asp Cys Ile Thr Gly Glu 275 280 285 Asp Glu Val Gly Cys Ala Gly Phe Ala Ser Val Ala Gln Glu Glu Thr 290 295 300 Glu Ile Leu Thr Ala Asp Met Asp Ala Glu Arg Arg Arg Ile Lys Ser 305 310 315 320 Leu Leu Pro Lys Leu Ser Cys Gly Val Lys Asn Arg Met His Ile Arg 325 330 335 Arg Lys Arg Ile Val Gly Gly Lys Arg Ala Gln Leu Gly Asp Leu Pro 340 345 350 Trp Gln Val Ala Ile Lys Asp Ala Ser Gly Ile Thr Cys Gly Gly Ile 355 360 365 Tyr Ile Gly Gly Cys Trp Ile Leu Thr Ala Ala His Cys Leu Arg Ala 370 375 380 Ser Lys Thr His Arg Tyr Gln Ile Trp Thr Thr Val Val Asp Trp Ile 385 390 395 400 His Pro Asp Leu Lys Arg Ile Val Ile Glu Tyr Val Asp Arg Ile Ile 405 410 415 Phe His Glu Asn Tyr Asn Ala Gly Thr Tyr Gln Asn Asp Ile Ala Leu 420 425 430 Ile Glu Met Lys Lys Asp Gly Asn Lys Lys Asp Cys Glu Leu Pro Arg 435 440 445 Ser Ile Pro Ala Cys Val Pro Trp Ser Pro Tyr Leu Phe Gln Pro Asn 450 455 460 Asp Thr Cys Ile Val Ser Gly Trp Gly Arg Glu Lys Asp Asn Glu Arg 465 470 475 480 Val Phe Ser Leu Gln Trp Gly Glu Val Lys Leu Ile Ser Asn Cys Ser 485 490 495 Lys Phe Tyr Gly Asn Arg Phe Tyr Glu Lys Glu Met Glu Cys Ala Gly 500 505 510 Thr Tyr Asp Gly Ser Ile Asp Ala Cys Lys Gly Asp Ser Gly Gly Pro 515 520 525 Leu Val Cys Met Asp Ala Asn Asn Val Thr Tyr Val Trp Gly Val Val 530 535 540 Ser Trp Gly Glu Asn Cys Gly Lys Pro Glu Phe Pro Gly Val Tyr Thr 545 550 555 560 Lys Val Ala Asn Tyr Phe Asp Trp Ile Ser Tyr His Val Gly Arg Pro 565 570 575 Phe Ile Ser Gln Tyr Asn Val 580

Claims

1. An adeno-associated virus (AAV) vector comprising a nucleotide sequence encoding factor I, or a fragment or derivative thereof.

2. The nucleotide sequence encoding the I factor or a fragment or derivative thereof comprises: (a) a nucleotide sequence encoding an amino acid sequence having at least 70% identity to SEQ ID NO: 1 or 9; (b) a nucleotide sequence having at least 70% identity to SEQ ID NO: 2 or 8, and (c) the nucleotide sequence of SEQ ID NO: 2 or 8 The AAV vector of claim 1, comprising a sequence selected from the group consisting of:

3. The AAV vector of claim 1 or 2, wherein the viral vector is in the form of a viral particle.

4. The AAV vector of claim 3, wherein the AAV viral particle comprises an AAV2 genome and an AAV2 capsid protein.

5. 5. The AAV vector of claim 1, wherein the nucleotide sequence encoding the I factor or a fragment or derivative thereof is operably linked to a CAG promoter, preferably a promoter having the nucleotide sequence of SEQ ID NO:

5.

6. A cell transfected with an AAV vector according to any one of claims 1 to 5.

7. A pharmaceutical composition comprising an AAV vector according to any one of claims 1 to 5 or a cell according to claim 6 in combination with a pharma- ceutical acceptable carrier, diluent or excipient.

8. 8. An AAV vector, cell or pharmaceutical composition according to any one of claims 1 to 7 for use in the treatment or prevention of a complement-mediated eye disorder.

9. 9. The AAV vector, cell or pharmaceutical composition for use according to claim 8, wherein the disorder is age-related macular degeneration (AMD) or diabetic retinopathy, preferably AMD.

10. The AAV vector, cell or pharmaceutical composition for use according to claim 9, wherein the AMD is dry AMD.

11. 11. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8 to 10, wherein the formation of geographic atrophy is prevented or reduced and / or the amount of geographic atrophy is reduced.

12. 11. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8 to 10, for delaying the progression of geographic atrophy.

13. The AAV vector, cell or pharmaceutical composition for use according to claim 12, wherein there is at least a 10% reduction in the increase in the area of ​​geographic atrophy over a period of 12 months following administration to the treated eye of a subject, compared to the untreated eye over the same period.

14. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8 to 13, wherein administration of said AAV vector, cell or pharmaceutical composition increases the level of C3b-inactivating activity and iC3b-degrading activity in the subject or in the subject's eye, e.g. in the subject's retinal pigment epithelium (RPE), optionally to a level above normal levels in the subject, or in the eye or RPE.

15. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8 to 14, wherein the AAV vector, cell or pharmaceutical composition is administered intraocularly.

16. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8 to 15, wherein the AAV vector, cell or pharmaceutical composition is administered to the eye of the subject by subretinal injection, direct retinal injection, suprachoroidal injection or intravitreal injection.

17. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8 to 16, wherein the AAV vector, cell or pharmaceutical composition is administered to the eye of the subject by subretinal injection.

18. A method for treating or preventing a complement-mediated eye disorder, comprising administering to a subject in need thereof an AAV vector, cell or pharmaceutical composition described in any one of claims 1 to 7.

19. 19. The method of claim 18, wherein the disorder is age-related macular degeneration (AMD) or diabetic retinopathy, preferably AMD.

20. 20. The method of claim 19, wherein the AMD is dry AMD.

21. The method according to any one of claims 18 to 20, wherein the formation of geographic atrophy is prevented or reduced and / or the amount of geographic atrophy is reduced.

22. The method according to any one of claims 18 to 20, which slows the progression of geographic atrophy.

23. 23. The method of claim 22, wherein over a period of 12 months following administration to the treated eye of the subject, there is at least a 10% reduction in the increase in area of ​​geographic atrophy compared to the untreated eye over the same period.

24. The method of any one of claims 18 to 23, wherein administration of the AAV vector, cell or pharmaceutical composition increases the level of C3b-inactivating activity and iC3b-degrading activity in the subject or in the subject's eye, e.g. in the subject's retinal pigment epithelium (RPE), optionally to a level above normal levels in the subject, or in the eye or RPE.

25. The method according to any one of claims 18 to 24, wherein the AAV vector, cell or pharmaceutical composition is administered intraocularly.

26. The method of any one of claims 18 to 25, wherein the AAV vector, cell or pharmaceutical composition is administered to the subject's eye by subretinal injection, direct retinal injection, suprachoroidal injection or intravitreal injection.

27. The method of any one of claims 18 to 26, wherein the AAV vector, cell or pharmaceutical composition is administered to the subject's eye by subretinal injection.

28. An adeno-associated virus (AAV) vector comprising a nucleotide sequence encoding Factor H or a fragment or derivative thereof.

29. The nucleotide sequence encoding the factor H or a fragment or derivative thereof comprises: (a) a nucleotide sequence encoding an amino acid sequence having at least 70% identity to SEQ ID NO:3; (b) a nucleotide sequence having at least 70% identity to SEQ ID NO:4, and (c) the nucleotide sequence of SEQ ID NO:4 The AAV vector of claim 28, comprising a sequence selected from the group consisting of:

30. 30. The AAV vector of claim 28 or 29, wherein the viral vector is in the form of a viral particle.

31. The AAV vector of claim 30, wherein the AAV viral particle comprises an AAV2 genome and an AAV2 capsid protein.

32. 32. The AAV vector of any one of claims 28 to 31, wherein the nucleotide sequence encoding factor H or a fragment or derivative thereof is operably linked to a CAG promoter, preferably a promoter having the nucleotide sequence of SEQ ID NO:

5.

33. A cell transfected with an AAV vector according to any one of claims 28 to 32.

34. A pharmaceutical composition comprising an AAV vector according to any one of claims 28 to 32, or a cell according to claim 33, in combination with a pharma- ceutical acceptable carrier, diluent or excipient.

35. 35. The AAV vector, cell or pharmaceutical composition according to any one of claims 28 to 34 for use in the treatment or prevention of a complement mediated eye disorder, preferably wherein the disorder is age-related macular degeneration (AMD) or diabetic retinopathy, preferably AMD, preferably dry AMD.

36. 36. The AAV vector, cell or pharmaceutical composition for use according to claim 35, wherein the AAV vector is for use as defined in any one of claims 9 to 17.